



C.V. Iraj Sharifi

Iraj Sharifi was born in Jiroft, Iran. He attended Amir Kabir High School and received his Diploma in Natural Sciences in 1968. Upon graduation from high school he attended Tabriz University & received his B.S in Biology in 1973. He continued his higher education in the U.S.A at **Western Illinois University** in 1974 and received his **M.S in Biological Sciences with major in Parasitology** in 1977. He transferred to the **University of Illinois** in 1977 to pursue his **Ph.D in Veterinary Medical Sciences (Parasitology)** and received his Ph.D degree in 1981. Ever since, he has been **teaching (700 units)** and doing research works (publishing over **100 research articles, took 80 research projects and 3 TDR/WHO projects**) in School of Medicine, Kerman University of Medical Sciences.

Now, he is **a full Distinguished Professor** in Parasitology at School of Medicine and Leishmaniasis Research Center. He has been a PI of two vaccine projects entitled "Randomized Field Trials of Single and Multiple Doses of ALM Vaccine Efficacy against ACL in Bam, Iran" which was published in **the Lancet**.

Besides teaching Parasitology in School of Medicine he trains M.S and PhD in Medical Parasitology and he had several positions (**13.5 years chancellor, 20 years Dean, Vice-Chancellor and Director**) and the following publications and presentations:

CV links:

[Google Scholar](#)

[Scopus](#)

[ISID](#)

1. Articles

1. Zarrinkar F, **Sharifi I**, Salarkia E., Keyhani A., Babaei Z, Khamesipour A, Hakimi Parizi M, Mollakbari E, Sharifi F, Dabiri S, Bamorovat M. Assessment of the antileishmanial activity of diallyl sulfide combined with meglumine antimoniate on *Leishmania major*: Molecular docking, in vitro, and animal model. *Plos One*. 2024;19(8):e0307537.
2. Sharifi F, Mohamadi N, Abiri A, **Sharifi I**, Harandi MF, Sharififar F. Nature-derived Alkaloids as a Promising Bioactive Compound in Drug Discovery to Meet Global Leishmania Needs. *Letters in Drug Design & Discovery*. 2024;21(1):34-61.
3. Shahsavari S, **Sharifi I**, Salarkia E, Keyhani A, Sharifi F, Babaei Z. In silico and experimental potentials of 6-shogaol and meglumine antimoniate on *Leishmania major*: multiple synergistic combinations through modulation of biological properties. *Immunologic Research*. 2024:1-14.
4. Seyedi F, **Sharifi I**, Khosravi A, Molaakbari E, Tavakkoli H, Salarkia E, et al. Comparison of cytotoxicity of Miltefosine and its niosomal form on chick embryo model. *Scientific Reports*. 2024;14(1):2482.
5. Jafarzadeh A, Kumar S, Bodhale N, Jafarzadeh S, Nemati M, **Sharifi I**, et al. PD-1/PD-L1 and PD-1/PD-L2 axes-targeted anti-leishmanial therapy. *Authorea Preprints*. 2024.
6. Jafarzadeh A, Gurjar D, Bodhale N, Jafarzadeh S, Nemati M, **Sharifi I**, et al. Aberrant expression of SOCS impairs the anti-leishmanial immune response. *Cytokine*. 2024;174:156461.
7. Bamorovat M, **Sharifi I**, Shafiei Bafti M, Agha Kuchak Afshari S, Aflatoonian MR, Karamoozian A, et al. Cutaneous Leishmaniasis Hampers COVID-19: A Controlled Cross-Sectional Study in High-Burden Endemic Areas of Iran. *Journal of Epidemiology and Global Health*. 2024;14(1):142-53.
8. Bamorovat M, **Sharifi I**, Khosravi A, Aflatoonian MR, Agha Kuchak Afshari S, Salarkia E, et al. Global Dilemma and Needs Assessment Toward Achieving Sustainable Development Goals in Controlling Leishmaniasis. *Journal of Epidemiology and Global Health*. 2024;14(1):22-34.
9. Bamorovat M, **Sharifi I**, Aflatoonian MR, Salarkia E, Afshari SAK, Pourkhosravani M, et al. A prospective longitudinal study on the elimination trend of rural cutaneous leishmaniasis in southeastern Iran: climate change, population displacement, and agricultural transition from 1991 to 2021. *Science of the Total Environment*. 2024;913:169684.

10. Afshar AA, Gorouhi MA, **Sharifi I**, Yousefi S, Faraji M, Afshar PJ, et al. Application of Rodenticides for the Control of Zoonotic Cutaneous Leishmaniasis in Iran: A Systematic Review of the Literature. *Journal of Environmental Health and Sustainable Development*. 2024.
11. **Sharifi I**, Khosravi A, Aflatoonian MR, Salarkia E, Bamorovat M, Karamoozian A, et al. Cutaneous leishmaniasis situation analysis in the Islamic Republic of Iran in preparation for an elimination plan. *Frontiers in Public Health*. 2023;11:1091709.
12. Sharifi F, **Sharifi I**, Ohadi M, Mohamadi N, Salarkia E, Banat IM, et al. The potential role of lipopeptide biosurfactant generated by *Acinetobacter junii* B6 on *Leishmania tropica*: The synergy of lipopeptide biosurfactant and Glucantime. *International Journal of Peptide Research and Therapeutics*. 2023;29(4):57.
13. Sharifi F, **Sharifi I**, Babaei Z, Alahdin S, Afgar A. Bioinformatics evaluation of anticancer properties of GP63 protein-derived peptides on MMP2 protein of melanoma cancer. *Journal of Pathology Informatics*. 2023;14:100190.
14. Sharifi F, Seyedi F, Mohamadi N, **Sharifi I**, Pardakhty A, Khosravi A, et al. Cytotoxicity Effects of Miltefosine and Niosomal form on Human Umbilical Vein Endothelial Cells: Colorimetric Assay, Apoptosis, and Gene Expression Profiling. *Letters in Drug Design & Discovery*. 2023;20(12):1936-46.
15. Sharifi F, Mohamadi N, Tavakoli Oliaee R, **Sharifi I**, Doostmohammadi M, Soltanian S, et al. The potential effect of silver nanoparticles synthesized with *Coffea arabica* green seeds on *Leishmania major* proliferation, cytotoxicity activity, and cytokines expression level. *Journal of Parasitic Diseases*. 2023;47(1):131-9.
16. Salarkia E, **Sharifi I**, Keyhani A, Tavakoli Oliaee R, Khosravi A, Sharifi F, et al. In silico and in vitro potentials of crocin and amphotericin B on *Leishmania major*: Multiple synergistic mechanisms of actions. *Plos one*. 2023;18(9):e0291322.
17. Salarkia E, Mehdipoor M, Molaakbari E, Khosravi A, Sazegar MR, Salari Z, et al. Exploring mesoporous silica nanoparticles as oral insulin carriers: In-silico and in vivo evaluation. *Heliyon*. 2023;9(10).
18. Salari Z, Khosravi A, Pourkhandani E, Molaakbari E, Salarkia E, Keyhani A, et al. The inhibitory effect of 6-gingerol and cisplatin on ovarian cancer and antitumor activity: In silico, in vitro, and in vivo. *Frontiers in oncology*. 2023;13:1098429.
19. Mohamadi N, **Sharifi I**, Afgar A, Sharififar F, Sharifi F. Antileishmanial effects of *Bunium persicum* crude extract, essential oil, and cuminaldehyde on *Leishmania major*: In silico and in vitro properties. *Acta Parasitologica*. 2023;68(1):103-13.

20. Mirzaei M, **Sharifi I**, Mohammad-Rafi F, Anjomshoa M, Abiri A, Moqaddari AH, et al. Antileishmanial effects and drugability characteristics of a heterocyclic copper complex: An in silico, in vitro and molecular study. *Journal of Inorganic Biochemistry*. 2023;245:112245.
21. Hajhosseini M, **Sharifi I**, Bamorovat M, Karamoozian A, Amanizadeh A, Agha Kuchak Afshari S. Monitoring of airborne fungi during the second wave of COVID-19 in selected wards of the referral university hospital in southeastern Iran. *Environmental Monitoring and Assessment*. 2023;195(9):1132.
22. Ghatee MA, **Sharifi I**, Mohammadi N, Moghaddam BE, Kohansal MH. Geographical and climatic risk factors of cutaneous leishmaniasis in the hyper-endemic focus of Bam County in southeast Iran. *Frontiers in Public Health*. 2023;11:1236552.
23. Derakhshani A, **Sharifi I**, Salarkia E, Keyhani A, Agha Kuchak Afshari S, Iranmanesh B, et al. Antileishmanial potentials of azacitidine and along with meglumine antimoniate on *Leishmania major*: In silico prediction and in vitro analysis. *Plos one*. 2023;18(9):e0291321.
24. Bamorovat M, **Sharifi I**, Agha Kuchak Afshari S, Ghasemi Nejad Almani P. Mutual role of patients and the healthcare system in the control of cutaneous leishmaniasis. *Transboundary and Emerging Diseases*. 2023;2023(1):7814940.
25. Bamorovat M, **Sharifi I**, Afshari SAK, Karamoozian A, Tahmouresi A, Heshmatkhah A, et al. Poor adherence is a major barrier to the proper treatment of cutaneous leishmaniasis: a case-control field assessment in Iran. *International Journal for Parasitology: Drugs and Drug Resistance*. 2023;21:21-7.
26. Bahraminejad S, Pardakhty A, **Sharifi I**, Keyhani A, Salarkia E, Ranjbar M. Synthesis and physicochemical characterization of Zn–Al layered double hydroxides (LDHs) as a delivery system for amphotericin B: In vitro and in silico antileishmanial study. *Heliyon*. 2023;9(4).
27. Salim Abadi Y, Sanei-Dehkordi A, Hakimi Parizi M, Aghaei Afshar A, **Sharifi I**, Gorouhi MA, et al. Baseline susceptibility of a wild strain of main vectors of leishmaniasis to WHO-recommended insecticides in southeastern Iran. *Parasites & Vectors*. 2022;15(1):42.
28. Salari S, Taghdiri A, Bamorovat M, **Sharifi I**, Almani PGN. A novel rapid LAMP test for identification of cutaneous leishmaniasis: An evaluation and comparative analysis of three molecular methods. *Microbial Pathogenesis*. 2022;169:105612.

29. Salari S, Bamorovat M, **Sharifi I**, Almani PGN. Global distribution of treatment resistance gene markers for leishmaniasis. *Journal of Clinical Laboratory Analysis*. 2022;36(8):e24599.
30. Rashno Z, **Sharifi I**, Oliaee RT, Tajbakhsh S, Sharififar F, Sharifi F, et al. Anti-leishmanial activity of *Avicennia marina* (Avicenniaceae family) leaves hydroalcoholic extract and its possible cellular mechanisms. *Parasite Epidemiology and Control*. 2022;17:e00239.
31. Nooshadokht M, Mirzaei M, **Sharifi I**, Sharifi F, Lashkari M, Amirheidari B. In silico and in vitro antileishmanial effects of gamma-terpinene: Multifunctional modes of action. *Chemico-Biological Interactions*. 2022;361:109957.
32. Mohseni F, **Sharifi I**, Oliaee RT, Babaei Z, Mostafavi M, Almani PGN, et al. Antiproliferative properties of Turmerone on *Leishmania major*: Modes of action confirmed by antioxidative and immunomodulatory roles. *Comparative Immunology, Microbiology and Infectious Diseases*. 2022;84:101797.
33. Khosravi A, **Sharifi I**, Tavakkoli H, Molaakbari E, Bahraminegad S, Salarkia E, et al. Cytotoxicity of amphotericin B and AmBisome: In silico and in vivo evaluation employing the chick embryo model. *Frontiers in Pharmacology*. 2022;13:860598.
34. Khaksar Baniasadi A, Ayatollahi Mosavi SA, **Sharifi I**, Bamorovat M, Salari S, Ahmadi A, et al. Vulvovaginal candidiasis in Iranian women: Molecular identification and antifungal susceptibility pattern. *Journal of Obstetrics and Gynaecology Research*. 2022;48(12):3292-303.
35. Javadi A, Khamesipour A, Ghoorchi M, Bahrami M, Khatami A, **Sharifi I**, et al. Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by *L. tropica* in Iran: A randomized controlled clinical trial. *PLoS Neglected Tropical Diseases*. 2022;16(7):e0010569.
36. Jafarzadeh A, Nemati M, Aminizadeh N, Bodhale N, Sarkar A, Jafarzadeh S, et al. Bidirectional cytokine-microRNA control: A novel immunoregulatory framework in leishmaniasis. *PLoS Pathogens*. 2022;18(8):e1010696.
37. Jafarzadeh A, Kumar S, Bodhale N, Jafarzadeh S, Nemati M, **Sharifi I**, et al. The expression of PD-1 and its ligands increases in *Leishmania* infection and its blockade reduces the parasite burden. *Cytokine*. 2022;153:155839.
38. Bamorovat M, **Sharifi I**, Aflatoonian MR, Karamoozian A, Tahmouresi A, Jafarzadeh A, et al. Prophylactic effect of cutaneous leishmaniasis against COVID-19: a

case-control field assessment. *International Journal of Infectious Diseases*. 2022;122:155-61.

39. Bahraminejad S, Pardakhty A, **Sharifi I**, Ranjbar M, Karami-Mohajeri S, Sharifi F. Preparation and evaluation of physicochemical properties and anti-leishmanial activity of zirconium/tioxolone niosomes against *Leishmania major*. *Arabian Journal of Chemistry*. 2022;15(10):104156.

40. Bahrami F, Masoudzadeh N, Van Veen S, Persson J, Lari A, Sarvnaz H, et al. Blood transcriptional profiles distinguish different clinical stages of cutaneous leishmaniasis in humans. *Molecular Immunology*. 2022;149:165-73.

41. Babaei Z, Asadi A, **Sharifi I**, Borhani M, Ahmadi A, Kayhani A, et al. Evaluation of ostrich and camel sera as alternatives to commercial fetal bovine serum in axenic culture of *Leishmania tropica* and *Leishmania major* promastigotes. 2022.

42. Aflatoonian M, **Sharifi I**, Aflatoonian B, Salarkia E, Khosravi A, Tavakoli Oliaee R, et al. Fifty years of struggle to control cutaneous leishmaniasis in the highest endemic county in Iran: a longitudinal observation inferred with interrupted time series model. *PLoS Neglected Tropical Diseases*. 2022;16(4):e0010271.

43. Tavakkoli H, Khosravi A, **Sharifi I**, Salari Z, Salarkia E, Kheirandish R, et al. Partridge and embryonated partridge egg as new preclinical models for candidiasis. *Scientific Reports*. 2021;11(1):2072.

44. **Sharifi I**, Tabatabaie F, Nikpour S, Mostafavi M, Tavakoli Oliaee R, Sharifi F, et al. The effect of *Naja naja oxiana* snake venom against *Leishmania tropica* confirmed by advanced assays. *Acta Parasitologica*. 2021;66:475-86.

45. **Sharifi I**. The in vitro effect of alcoholic extract of *Laurus nobilis* leaves on *Leishmania major* promastigote stage by colorimetric assay. 2021.

46. Sharifi F, Sharififar F, Pournamdari M, Ansari M, Tavakoli Oliaee R, Bamorovat M, et al. Leishmanicidal potentials of *Gossypium hirsutum* extract and its fractions on *Leishmania major* in a murine model: parasite burden, gene expression, and histopathological profile. *Journal of Medical Microbiology*. 2021;70(6):001333.

47. Sezavar M, **Sharifi I**, Ghasemi Nejad Almani P, Kazemi B, Davoudi N, Salari S, et al. The potential therapeutic role of PTR1 gene in non-healing anthroponotic cutaneous leishmaniasis due to *Leishmania tropica*. *Journal of Clinical Laboratory Analysis*. 2021;35(3):e23670.

48. Salari S, **Sharifi I**, Bamorovat M, Almani PGN. The immunity of the recombinant prokaryotic and eukaryotic subunit vaccines against cutaneous leishmaniasis. *Microbial pathogenesis*. 2021;153:104807.

49. Raessi M, Alijani HQ, Nematollahi FF, Baty RS, Batiha GE-S, Khan AU, et al. Barium carbonate nanostructures: Biosynthesis and their biomedical applications. *Ceramics International*. 2021;47(15):21045-50.
50. Nikpour S, Tabatabaie F, **Sharifi I**, Mostafavi M, Oliaee RT, Sharifi F, et al. The fraction of the snake venom, its leishmanicidal effect, and the stimulation of an anti-leishmania response in infected macrophages. *Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders)*. 2021;21(6):1115-24.
51. Nik Aein I, Sharifi-Sirchi G, **Sharifi I**. The in vitro effect of alcoholic extract of *Laurus nobilis* leaves on *Leishmania major* promastigote stage by colorimetric assay. *Agricultural Biotechnology Journal* 13 (1), 75-92. *Agricultural Biotechnology Journal*. 2021;13(1):75-92.
52. Naderi A, **Sharifi I**, Aflatoonian MR, Mostafavi M, Parizi MH, Mashayekhi J, et al. *Dirofilariosis* caused by *Dirofilaria immitis* in the south of Kerman province, Iran. *Microbial Pathogenesis*. 2021;154:104863.
53. Mostafavi M, **Sharifi I**, Asadikaram G, Nakhaee N, Kakooei S, Aflatoonian MR, et al. The impact of diabetes on cutaneous leishmaniasis. 2021.
54. Mostafavi M, **Sharifi I**, Asadikaram G, Nakhaee N, Kakooei S, Aflatoonian MR, et al. The impact of diabetes on cutaneous leishmaniasis: a case–control field assessment. *Parasitology Research*. 2021;120:3865-74.
55. Mirzaei M, Nadushan AS, Nooshadokht M, Abiri A, Anjomshoa M, **Sharifi I**, et al. In silico and in vitro inhibitory potential of an organometallic Cu (II) complex on *Leishmania major* stages. *Annals of Parasitology*. 2021;67(1).
56. Keyhani A, **Sharifi I**, Salarkia E, Khosravi A, Oliaee RT, Babaei Z, et al. In vitro and in vivo therapeutic potentials of 6-gingerol in combination with amphotericin B for treatment of *Leishmania major* infection: Powerful synergistic and multifunctional effects. *International Immunopharmacology*. 2021;101:108274.
57. Karimi T, **Sharifi I**, Aflatoonian MR, Aflatoonian B, Mohammadi MA, Salarkia E, et al. A long-lasting emerging epidemic of anthroponotic cutaneous leishmaniasis in southeastern Iran: population movement and peri-urban settlements as a major risk factor. *Parasites & Vectors*. 2021;14:1-14.
58. Javaheri E, **Sharifi I**, Bamorovat M, Barghbani R, Raiesi O, Zarandi MB, et al. New foci of zoonotic cutaneous leishmaniosis due to *Leishmania major* in the northeastern Iran cities of Sabzevar and Neghaab. *Annals of parasitology*. 2021;67(4).

59. Jafarzadeh A, Nair A, Jafarzadeh S, Nemati M, **Sharifi I**, Saha B. Immunological role of keratinocytes in leishmaniasis. *Parasite Immunology*. 2021;43(9):e12870.
60. Jafarzadeh A, Jafarzadeh S, **Sharifi I**, Aminizadeh N, Nozari P, Nemati M. The importance of T cell-derived cytokines in post-kala-azar dermal leishmaniasis. *Cytokine*. 2021;147:155321.
61. Ilaghi M, **Sharifi I**, Sharififar F, Sharifi F, Oliaee RT, Babaei Z, et al. The potential role and apoptotic profile of three medicinal plant extracts on *Leishmania tropica* by MTT assay, macrophage model and flow cytometry analysis. *Parasite Epidemiology and Control*. 2021;12:e00201.
62. Hadi T, Khosravi A, Iraj S, Zohreh S, Ehsan S, Reza K, et al. Partridge and embryonated partridge egg as new preclinical models for candidiasis. *Scientific Reports* (Nature Publisher Group). 2021;11(1).
63. Bamorovat M, **Sharifi I**, Tavakoli Oliaee R, Jafarzadeh A, Khosravi A. Determinants of unresponsiveness to treatment in cutaneous leishmaniasis: a focus on anthroponotic form due to *Leishmania tropica*. *Frontiers in Microbiology*. 2021;12:638957.
64. Bamorovat M, **Sharifi I**, Rashedi E, Shafiiian A, Sharifi F, Khosravi A, et al. A novel diagnostic and prognostic approach for unresponsive patients with anthroponotic cutaneous leishmaniasis using artificial neural networks. *PLoS One*. 2021;16(5):e0250904.
65. Bamorovat M, **Sharifi I**, Oliaee RT, Aflatoonian MR, Almani PGN, Derakhshani A, et al. Linguatulosus in small ruminants in southeastern Iran: epidemiological, histopathological and phylogenetic findings and its public health importance. *Microbial Pathogenesis*. 2021;152:104600.
66. Bamorovat M, **Sharifi I**, Dabiri S, Shamsi Meymandi S, Karamoozian A, Amiri R, et al. Major risk factors and histopathological profile of treatment failure, relapse and chronic patients with anthroponotic cutaneous leishmaniasis: a prospective case-control study on treatment outcome and their medical importance. *PLoS neglected tropical diseases*. 2021;15(1):e0009089.
67. Bahraminegad S, Pardakhty A, **Sharifi I**, Ranjbar M. Therapeutic effects of the as-synthesized polylactic acid/chitosan nanofibers decorated with amphotricin B for in vitro treatment of leishmaniasis. *Journal of Saudi Chemical Society*. 2021;25(11):101362.
68. Bahraminegad S, Pardakhty A, **Sharifi I**, Ranjbar M. The assessment of apoptosis, toxicity effects and anti-leishmanial study of Chitosan/CdO core-shell nanoparticles, eco-friendly synthesis and evaluation. *Arabian Journal of Chemistry*. 2021;14(4):103085.

69. Alizadeh I, Gorouhi MA, **Sharifi I**, Zamaninasab Z, Hazratian T, Aghaei Afshar A. Risk factors of anthroponotic cutaneous leishmaniasis among residents in endemic communities in southeast of Iran in 2019. *Journal of Environmental Health and Sustainable Development*. 2021;6(1):1219-30.
70. Albalawi AE, Alanazi AD, **Sharifi I**, Ezzatkah F. A systematic review of curcumin and its derivatives as valuable sources of antileishmanial agents. *Acta Parasitologica*. 2021;66:797-811.
71. Akhtardanesh B, Mostafavi M, Khedri J, Fakhri A, **Sharifi I**, Shahraki MK. Seroepidemiology of visceral leishmaniasis among free-roaming dogs and children in Zahedan city, southeast of Iran, 2018–2020. *Elsevier*; 2021. p. 105234.
72. Shirvani G, Fasihi-Harandi M, Raiesi O, Bazargan N, Zahedi MJ, **Sharifi I**, et al. Prevalence and molecular subtyping of *Blastocystis* from patients with irritable bowel syndrome, inflammatory bowel disease and chronic urticaria in Iran. *Acta parasitologica*. 2020;65:90-6.
73. Shabandoust H, **Sharifi I**, Raiesi O, Getso MI, Dezaki Saedi E, Afgar A, et al. Serum 25-hydroxyvitamin D level and vitamin D receptor (VDR) polymorphisms in patients infected with *Leishmania tropica*: a case control study. *Journal of Parasitic Diseases*. 2020;44:40-8.
74. Salari S, **Sharifi I**, Keyhani AR, Ghasemi Nejad Almani P. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice. *Parasites & vectors*. 2020;13:1-16.
75. Parsa R, Sedighi A, **Sharifi I**, Bamorovat M, Nasibi S. Molecular characterization of ocular dirofilariasis: a case report of *Dirofilaria immitis* in south-eastern Iran. *BMC Infectious Diseases*. 2020;20:1-5.
76. Oliaee RT, **Sharifi I**, Bamorovat M, Keyhani A, Babaei Z, Salarkia E, et al. The potential role of nicotinamide on *Leishmania tropica*: An assessment of inhibitory effect, cytokines gene expression and arginase profiling. *International Immunopharmacology*. 2020;86:106704.
77. Mohammadi MA, Bamorovat M, **Sharifi I**, Mostafavi M, Zarandi MB, Kheirandish R, et al. *Linguatula serrata* in cattle in southeastern Iran: Epidemiological, histopathological and phylogenetic profile and its zoonotic importance. *Veterinary Parasitology: Regional Studies and Reports*. 2020;22:100465.
78. Keyhani A, **Sharifi I**, Bamorovat M, Mohammadi MA, Askari A, Ebrahimipour M, et al. Epidemiological and molecular studies on *Echinococcus granulosus* from free-roaming dogs in Southeast Iran. *Veterinary World*. 2020;13(4):739.

79. Keyhani A, **Sharifi I**, Bamorovat M, Mohammadi M, Askari A, Ebrahimipour M, et al., editors. Epidemiological and molecular studies on *Echinococcus granulosus* from free-roaming dogs in Southeast Iran, *Veterinary World*, 13 (4): 739-745 2020: Abstract.
80. Jafarzadeh A, Nemati M, Chauhan P, Patidar A, Sarkar A, **Sharifi I**, et al. Interleukin-27 functional duality balances leishmania infectivity and pathogenesis. *Frontiers in immunology*. 2020;11:1573.
81. Asadi A, Tavakoli Kareshk A, **Sharifi I**, Firouzeh N. Murine cathelicidin: as a host defensive response against *Leishmania major* infection. *Journal of Parasitic Diseases*. 2020;44:633-8.
82. Alizadeh I, Gorouhi MA, Afshar AA, **Sharifi I**, Zamaninasab Z. Anthroponotic Cutaneous Leishmaniasis: Knowledge, Attitudes, Practices, and Risk Factors among residents in endemic Communities in Kerman City in the Southeast of Iran. *Authorea Preprints*. 2020.
83. Akhtardanesh B, Moeini E, **Sharifi I**, Saberi M, Sadeghi B, Ebrahimi M, et al. *Leishmania* infection in cats positive for immunodeficiency virus and feline leukemia virus in an endemic region of Iran. *Veterinary Parasitology: Regional Studies and Reports*. 2020;20:100387.
84. Akhtardanesh B, Ghoreishi S, Jajarmi M, **Sharifi I**. Seroepidemiology of visceral leishmaniasis in stray dogs in Yazd city by ELISA method. *Iranian Journal of Veterinary Clinical Sciences*. 2020;14(2).
85. Tohidi F, Kazemi B, Bandehpour M, **Sharifi I**, Rabiei MR, Dezaki ES, et al. Transient down-regulation of nucleoside transporter 3 gene expression as a drug target in *leishmania major* using antisense RNA technology. *Iranian Journal of Parasitology*. 2019;14(1):111.
86. Tohidi F, Babaei Z, Kazemi B, Bandehpour M, **Sharifi I**, Rabiei MR, et al. Transient knockdown of Nucleoside transporter 4 gene expression as a therapeutic target in *Leishmania major* by antisense RNA: In vitro: and in vivo studies. *Journal of vector borne diseases*. 2019;56(2):98-104.
87. Taghdiri A, Almani PGN, **Sharifi I**, Mohammadi MA, Salari S. Detection of malaria with light microscopy and Nested polymerase chain reaction (Nested PCR) methods in peripheral blood expansions and investigation of the genetic diversity of *Plasmodium* species by 18S rRNA gene in Southeast of Iran. *Microbial pathogenesis*. 2019;137:103782.
88. **Sharifi I**, Aflatoonian MR, Babaei Z, Sharifi F, Keyhani A, Salarkia E, et al. Emerging epidemics of cutaneous leishmaniasis in Iran: operational aspects, management

and implemented control approaches. *Journal of Medical Microbiology and Infectious Diseases*. 2019;7(3):52-60.

89. Sharifi F, **Sharifi I**, Keyhani A, Asadi-Khanuki A, Sharififar F, Pournamdari M. Leishmanicidal, cytotoxic and apoptotic effects of *Gossypium hirsutum* bulb extract and its separated fractions on *Leishmania major*. *Journal of Vector Borne Diseases*. 2019;56(4):330-8.

90. Saduqi M, **Sharifi I**, Babaei Z, Keyhani A, Mostafavi M, Parizi MH, et al. Anti-leishmanial and immunomodulatory effects of epigallocatechin 3-o-gallate on *leishmania tropica*: Apoptosis and gene expression profiling. *Iranian Journal of Parasitology*. 2019;14(4):521.

91. Razavinasab SZ, **Sharifi I**, Aflatoonian MR, Babaei Z, Mohammadi MA, Salarkia E, et al. Expansion of urban cutaneous leishmaniasis into rural areas of southeastern Iran: Clinical, epidemiological and phylogenetic profiles explored using 7SL high resolution melting-PCR analysis. *Transboundary and emerging diseases*. 2019;66(4):1602-10.

92. Parizi MH, **Sharifi I**, Farajzadeh S, Pardakhty A, Parizi MHD, Sharifi H, et al. Tioxolone niosomes exert antileishmanial effects on *Leishmania tropica* by promoting promastigote apoptosis and immunomodulation. *Asian Pacific Journal of Tropical Medicine*. 2019;12(8):365-74.

93. Parizi MH, Pardakhty A, Farajzadeh S, Parizi MHD, Sharifi H, Keyhani AR, et al. Antileishmanial activity and immune modulatory effects of benzoxonium chloride and its entrapped forms in niosome on *Leishmania tropica*. *Journal of Parasitic Diseases: Official Organ of the Indian Society for Parasitology*. 2019;43(3):406.

94. Parizi MH, Farajzadeh S, **Sharifi I**, Pardakhty A, Parizi MHD, Sharifi H, et al. Antileishmanial activity of niosomal combination forms of tioxolone along with benzoxonium chloride against *Leishmania tropica*. *The Korean journal of parasitology*. 2019;57(4):359.

95. Oliaee RT, **Sharifi I**, Afgar A, Jafarzadeh A, Kareshk AT, Bamorovat M, et al. Differential expression of TLRs 2, 4, 9, iNOS and TNF- α and arginase activity in peripheral blood monocytes from glucantime unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis caused by *Leishmania tropica*. *Microbial pathogenesis*. 2019;126:368-78.

96. Mostafavi M, **Sharifi I**, Farajzadeh S, Khazaeli P, Sharifi H, Pourseyedi E, et al. Niosomal formulation of amphotericin B alone and in combination with glucantime: In vitro and in vivo leishmanicidal effects. *Biomedicine & Pharmacotherapy*. 2019;116:108942.

97. Mostafavi M, Khazaeli P, **Sharifi I**, Farajzadeh S, Sharifi H, Keyhani A, et al. A novel niosomal combination of selenium coupled with glucantime against *Leishmania tropica*. *The Korean journal of parasitology*. 2019;57(1):1.
98. Mostafavi M, Farajzadeh S, **Sharifi I**, Khazaeli P, Sharifi H. Leishmanicidal effects of amphotericin B in combination with selenium loaded on niosome against *Leishmania tropica*. *Journal of Parasitic Diseases*. 2019;43:176-85.
99. Mehravaran A, Nasab MR, Mirahmadi H, **Sharifi I**, Alijani E, Nikpoor AR, et al. Immunogenicity and protection effects of cationic liposome containing imiquimod adjuvant on leishmaniasis in BALB/c mice. *Iranian Journal of Basic Medical Sciences*. 2019;22(8):922.
100. Mehravaran A, Nasab MR, Mirahmadi H, **Sharifi I**, Alijani E, Nikpoor AR, et al. Protection induced by *Leishmania* Major antigens and the imiquimod adjuvant encapsulated on liposomes in experimental cutaneous leishmaniasis. *Infection, Genetics and Evolution*. 2019;70:27-35.
101. Khosravi A, **Sharifi I**, Tavakkoli H, Keyhani AR, Afgar A, Salari Z, et al. Toxicopathological effects of meglumine antimoniate on human umbilical vein endothelial cells. *Toxicology in Vitro*. 2019;56:10-8.
102. Jafarzadeh A, Nemati M, **Sharifi I**, Nair A, Shukla D, Chauhan P, et al. *Leishmania* species-dependent functional duality of toll-like receptor 2. *IUBMB life*. 2019;71(11):1685-700.
103. Hakimi Parizi M, Pardakhty A, **Sharifi I**, Farajzadeh S, Daie Parizi MH, Sharifi H, et al. Antileishmanial activity and immune modulatory effects of benzoxonium chloride and its entrapped forms in niosome on *leishmania tropica*. *Journal of Parasitic Diseases*. 2019;43:406-15.
104. Ezatkhah F, **Sharifi I**, Babaei Z, Baneshi M, Zolala F, Kermanizadeh A, et al. Clinical and laboratory evaluation of cured and non-cured patients with cutaneous leishmaniasis treated by Glucantime. *Journal of Vector Borne Diseases*. 2019;56(4):351-9.
105. Bamorovat M, **Sharifi I**, Fekri A, Keyhani A, Aflatoonian MR, Heshmatkhah A, et al. A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models. *Microbial pathogenesis*. 2019;128:162-70.
106. Bamorovat M, **Sharifi I**, Aflatoonian MR, Sadeghi B, Shafiian A, Oliae RT, et al. Host's immune response in unresponsive and responsive patients with anthroponotic

cutaneous leishmaniasis treated by meglumine antimoniate: A case-control study of Th1 and Th2 pathways. *International immunopharmacology*. 2019;69:321-7.

107. Aflatoonian MR, **Sharifi I**, Aflatoonian B, Bamorovat M, Heshmatkhah A, Babaei Z, et al. Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran. *PLoS neglected tropical diseases*. 2019;13(6):e0007423.

108. Aflatoonian M, Nadim A, **Sharifi I**, Bamorevat M, Tajik S, Hashmian M, et al. Comparison of morbidity rate and transmission cycle of cutaneous leishmaniasis in two new foci in east and southeast of Kerman, 2017. 2019.

109. Sharifi F, Sharififar F, **Sharifi I**, Alijani HQ, Khatami M. Cytotoxicity, leishmanicidal, and antioxidant activity of biosynthesised zinc sulphide nanoparticles using *Phoenix dactylifera*. *Iet Nanobiotechnology*. 2018;12(3):264-9.

110. Sharifi F, **Sharifi I**, Pournamdari M, Sharififar F. Antileishmanial effect of *coffea arabica*, *salvia rhytidea* and *bunium persicum* against *leishmania major* and *leishmania tropica* promastigotes and their cytotoxicity and antioxidant activities. *European J Med Plants*. 2018;1(2):1-10.

111. Shaddel M, **Sharifi I**, Karvar M, Keyhani A, Baziar Z. Cryotherapy of cutaneous leishmaniasis caused by *Leishmania major* in BALB/c mice: A comparative experimental study. *Journal of Vector Borne Diseases*. 2018;55(1):42-6.

112. Ramezany M, **Sharifi I**, Babaei Z, Ghasemi Nejad Almani P, Heshmatkhah A, Keyhani A, et al. Geographical distribution and molecular characterization for cutaneous leishmaniasis species by sequencing and phylogenetic analyses of kDNA and ITS1 loci markers in south-eastern Iran. *Pathogens and Global Health*. 2018;112(3):132-41.

113. Oliabee RT, **Sharifi I**, Afgar A, Kareshk AT, Asadi A, Heshmatkhah A, et al. Unresponsiveness to meglumine antimoniate in anthroponotic cutaneous leishmaniasis field isolates: analysis of resistance biomarkers by gene expression profiling. *Tropical Medicine & International Health*. 2018;23(6):622-33.

114. Mohammadiha A, Dalimi A, Mohebbi M, **Sharifi I**, Mahmoudi M, Mirzaei A, et al. Molecular identification and phylogenetic classification of *Leishmania* spp. isolated from human cutaneous leishmaniasis in Iran: A cross-sectional study. *Iranian journal of parasitology*. 2018;13(3):351.

115. Khosravi A, **Sharifi I**, Tavakkoli H, Keyhani AR, Afgar A, Salari Z, et al. Vascular apoptosis associated with meglumine antimoniate: In vivo investigation of a chick embryo model. *Biochemical and biophysical research communications*. 2018;505(3):794-800.

116. Khosravi A, **Sharifi I**, Tavakkoli H, Derakhshanfar A, Keyhani AR, Salari Z, et al. Embryonic toxico-pathological effects of meglumine antimoniate using a chick embryo model. *PLoS One*. 2018;13(5):e0196424.
117. Khedri J, Radfar M, **Sharifi I**. Potential demographic, clinical, and environment risk factors for canine visceral leishmaniasis using IFAT and nested PCR, southeastern Iran. *Comparative Clinical Pathology*. 2018;27:275-81.
118. Khatami M, Zafarnia N, Bami MH, **Sharifi I**, Singh H. Antifungal and antibacterial activity of densely dispersed silver nanospheres with homogeneity size which synthesized using chicory: An in vitro study. *Journal de mycologie medicale*. 2018;28(4):637-44.
119. Khatami M, **Sharifi I**, Nobre MA, Zafarnia N, Aflatoonian MR. Waste-grass-mediated green synthesis of silver nanoparticles and evaluation of their anticancer, antifungal and antibacterial activity. *Green Chemistry Letters and Reviews*. 2018;11(2):125-34.
120. Khatami M, Alijani HQ, **Sharifi I**. Biosynthesis of bimetallic and core-shell nanoparticles: their biomedical applications—a review. *IET nanobiotechnology*. 2018;12(7):879-87.
121. Khatami M, Alijani HQ, Heli H, **Sharifi I**. Rectangular shaped zinc oxide nanoparticles: Green synthesis by Stevia and its biomedical efficiency. *Ceramics International*. 2018;44(13):15596-602.
122. Ghatee MA, Mirhendi H, Marashifard M, Kanannejad Z, Taylor WR, **Sharifi I**. Research Article Population Structure of *Leishmania tropica* Causing Anthroponotic Cutaneous Leishmaniasis in Southern Iran by PCR-RFLP of Kinetoplastid DNA. 2018.
123. Ghatee MA, Mirhendi H, Marashifard M, Kanannejad Z, Taylor WR, **Sharifi I**. Population Structure of *Leishmania tropica* Causing Anthroponotic Cutaneous Leishmaniasis in Southern Iran by PCR-RFLP of Kinetoplastid DNA. *BioMed research international*. 2018;2018(1):6049198.
124. Ghatee MA, Mirhendi H, Karamian M, Taylor WR, **Sharifi I**, Hosseinzadeh M, et al. Population structures of *Leishmania infantum* and *Leishmania tropica* the causative agents of kala-azar in Southwest Iran. *Parasitology research*. 2018;117:3447-58.
125. Daneshvar H, Kareshk AT, **Sharifi I**, Keyhani A, Oliae RT, Asadi A. Host-parasite responses outcome regulate the expression of antimicrobial peptide genes in the skin of balb/c and c57bl/6 murine strains following leishmania major mrho/ir/75/er infection. *Iranian Journal of Parasitology*. 2018;13(4):515.

126. Bamorovat M, **Sharifi I**, Mohammadi MA, Eybpoosh S, Nasibi S, Aflatoonian MR, et al. Leishmania tropica isolates from non-healed and healed patients in Iran: A molecular typing and phylogenetic analysis. Microbial pathogenesis. 2018;116:124-9.
127. Bamorovat M, **Sharifi I**, Aflatoonian MR, Sharifi H, Karamoozian A, Sharifi F, et al. Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran. PloS one. 2018;13(2):e0192236.
128. Askari A, **Sharifi I**, Aflatoonian M, Babaei Z, Almani PGN, Mohammadi M, et al. A newly emerged focus of zoonotic cutaneous leishmaniasis in South-Western Iran. Microbial pathogenesis. 2018;121:363-8.
129. Akhtardanesh B, Kheirandish R, **Sharifi I**, Mohammadi A, Mostafavi A, Mahmoodi T, et al. Low susceptibility of domestic cats to experimental Leishmania infantum infection. Journal of Vector Borne Diseases. 2018;55(3):230-4.
130. Afshar MJA, **Sharifi I**, Bamorovat M, Mohebbali M, Bahreini MS, Naderi A. Canine visceral leishmaniasis; A seroepidemiological survey in Jiroft district, southern Kerman province, southeastern Iran in 2015. Iranian Journal of Parasitology. 2018;13(1):67.
131. **Sharifi I**, Aflatoonian MR, Parizi MHD, Hosseininiasab A, Mostafavi M, Bamorovat M, et al. Visceral leishmaniasis in Southeastern Iran: a narrative review. Iranian journal of parasitology. 2017;12(1):1.
132. Sharifi F, Sharififar F, **Sharifi I**, Pournamdari M, Eslaminejad T, Khatami M. Antioxidant, anti-proliferation and cytotoxicity activities of Gossypium hirsutum toward standard HepG2, A549, MCF-7 and U87 cancer cell lines compared to HUVEC, 3T3 normal cells. Eur J Med Plants. 2017;21:1-10.
133. Salim-Abadi Y, Asadpour M, **Sharifi I**, Sanei-Dehkordi A, Gorouhi MA, Paksa A, et al. Baseline susceptibility of filarial vector Culex quinquefasciatus (Diptera: Culicidae) to five insecticides with different modes of action in southeast of Iran. Journal of Arthropod-Borne Diseases. 2017;11(4):453.
134. Nooshadokht M, **Sharifi I**, Mohammadi MA, Pirestani M, Afgar A, Mahootchi A, et al. Intestinal microsporidiosis in Iran: infection in immune-compromised and immunocompetent patients. Current Medical Mycology. 2017;3(1):30.
135. Nooshadokht M, Kalantari-Khandani B, **Sharifi I**, Kamyabi H, Liyanage NP, Lagenaur LA, et al. Stool antigen immunodetection for diagnosis of Giardia duodenalis infection in human subjects with HIV and cancer. Journal of microbiological methods. 2017;141:35-41.
136. Mortazavi SM, Khatami M, **Sharifi I**, Heli H, Kaykavousi K, Sobhani Poor MH, et al. Bacterial biosynthesis of gold nanoparticles using Salmonella enterica subsp. enterica

serovar Typhi isolated from blood and stool specimens of patients. *Journal of Cluster Science*. 2017;28:2997-3007.

137. Mohammadi MA, Bamorovat M, Harandi MF, Karimi T, **Sharifi I**, Aflatoonian MR. Comparison of three PCR-based methods for simplicity and cost effectiveness identification of cutaneous Leishmaniasis due to *Leishmania tropica*. *Iranian Journal of Parasitology*. 2017;12(2):215.

138. Mahmoudvand H, Kheirandish F, Mirbadie SR, Kayedi MH, Riabi TR, Ghasemi AA, et al. The potential use of methotrexate in the treatment of cutaneous leishmaniasis: in vitro assays against sensitive and meglumine antimoniate-resistant strains of *Leishmania tropica*. *Iranian journal of parasitology*. 2017;12(3):339.

139. Khosravi A, **Sharifi I**, Fekri A, Kermanizadeh A, Bamorovat M, Mostafavi M, et al. Clinical features of anthroponotic cutaneous leishmaniasis in a major focus, Southeastern Iran, 1994–2014. *Iranian journal of parasitology*. 2017;12(4):544.

140. Khatami M, Alijani H, **Sharifi I**, Sharifi F, Pourseyedi S, Kharazi S, et al. Leishmanicidal activity of biogenic Fe₃O₄ nanoparticles. *Scientia pharmaceutica*. 2017;85(4):36.

141. Ghatee MA, Kanannejad Z, **Sharifi I**, Askari A, Bamorovat M. Survey of False-positive Reactivity of Latex Agglutination Test for Kala-azar (Katex) without Urine Sample Boiling Process in Autoimmune Patients. *Iranian Journal of Public Health*. 2017;46(6):804.

142. Daneshvar H, **Sharifi I**, Keyhani A, Tavakoli Kareshk A, Asadi A. Comparative analysis of antimicrobial peptides gene expression in susceptible/resistant mice macrophages to *Leishmania major* infection. *Middle East J Fam Med*. 2017;7(10):18.

143. Bamorovat M, **Sharifi I**, Harandi MF, Nasibi S, Sadeghi B, Khedri J, et al. Parasitological, serological and molecular study of *Dirofilaria immitis* in domestic dogs, southeastern Iran. *Iranian Journal of Parasitology*. 2017;12(2):260.

144. Akhtardanesh B, **Sharifi I**, Mohammadi A, Mostafavi M, Hakimmipour M, Pourafshar NG. Feline visceral leishmaniasis in Kerman, southeast of Iran: serological and molecular study. *Journal of Vector Borne Diseases*. 2017;54(1):96-102.

145. Afshar AA, Parizi MH, **Sharifi I**, Gorouhi MA, Sharifi F, Baafi B. Evaluation of the ecological characteristics in the vector of anthroponotic cutaneous leishmaniasis in a new focus of Mohammad Abad, Kerman, southeast of Iran. *Asian Pac J Trop Dis*. 2017;7:84-7.

146. Aflatoonian M, Khatami M, **Sharifi I**, Pourseyedi S, Khatami M, Yaghobi H, et al. Evaluation antimicrobial activity of biogenic zinc oxide nanoparticles on two standard gram positive and gram negative strains. 2017.
147. Sharifi-Rad M, Dabirzadeh M, **Sharifi I**, Babaei Z. Leishmania major: genetic profiles of the parasites isolated from Chabahar, Southeastern Iran by PPIP-PCR. Iranian Journal of Parasitology. 2016;11(3):290.
148. Mahmoudvand H, Dezaki ES, Ezatpour B, **Sharifi I**, Kheirandish F, Rashidipour M. In vitro and in vivo antileishmanial activities of Pistacia vera essential oil. Planta medica. 2016;82(04):279-84.
149. Karvar M, **Sharifi I**, Daie Parizi MH, Baziar Z, Pouryazdanpanah N, Heshmatkhah A. The efficacy, relapse and failure in the treatment of anthroponotic cutaneous leishmaniasis with intralesional glucantime along with cryotherapy. Journal of Kerman University of Medical Sciences. 2016;23(2):156-63.
150. Farajzadeh S, Heshmatkhah A, Vares B, Mohebbi E, Mohebbi A, Aflatoonian M, et al. Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial. Journal of parasitic diseases. 2016;40:1159-64.
151. Babaei Z, Malihi N, Zia-Ali N, **Sharifi I**, Mohammadi MA, Kagnoff MF, et al. Adaptive immune response in symptomatic and asymptomatic enteric protozoal infection: evidence for a determining role of parasite genetic heterogeneity in host immunity to human giardiasis. Microbes and infection. 2016;18(11):687-95.
152. Almani PGN, **Sharifi I**, Kazemi B, Babaei Z, Bandehpour M, Salari S, et al. The role of GlcNAc-PI-de-N-acetylase gene by gene knockout through homologous recombination and its consequences on survival, growth and infectivity of Leishmania major in in vitro and in vivo conditions. Acta tropica. 2016;154:63-72.
153. Almani PGN, **Sharifi I**, Kazemi B, Babaei Z, Bandehpour M, Salari S, et al. Designing and cloning molecular constructs to knock out N-acetylglucosamine phosphatidylinositol De-N-acetylase (GPI12) gene in Leishmania major (MRHO/IR/75/ER). Iranian Journal of Parasitology. 2016;11(4):448.
154. Aflatoonian MR, **Sharifi I**, Aflatoonian B, Shirzadi MR, Gouya MM, Kermanizadeh A. A review of impact of bam earthquake on cutaneous leishmaniasis and status: epidemic of old foci, emergence of new foci and changes in features of the disease. Journal of arthropod-borne diseases. 2016;10(3):271.
155. Aflatoonian M, **Sharifi I**, Zeinali M, Bamorovat M, Aflatoonian B. Estimation of the Incidence of Cutaneous Leishmaniasis by Combining Two Longitudinal and Cross

sectional Studies in Kerman, Iran in 2009-2014. Iranian Journal of Epidemiology. 2016;12(2):1-8.

156. Aflatoonian M, **Sharifi I**, Shirzadi M, Aflatoonian B. The effect of active case detection and early treatment on the incidence rate of anthroponotic cutaneous leishmaniasis in Kerman province, Iran. 2016.

157. **Sharifi I**, Aflatoonian MR, Fekri AR, Parizi MH, Afshar AA, Khosravi A, et al. A comprehensive review of cutaneous leishmaniasis in kerman province, southeastern iran-narrative review article. Iranian journal of public health. 2015;44(3):299.

158. **Sharifi I**, Aflatoonian MR, Aflatoonian B, Kermanizadeh A. The severity of cutaneous leishmaniasis before and after the earthquake in Bam, southeastern Iran. Journal of Parasitic Diseases. 2015;39:741-4.

159. Nosratabadi SJ, **Sharifi I**, Sharififar F, Bamorovat M, Daneshvar H, Mirzaie M. In vitro antileishmanial activity of methanolic and aqueous extracts of Eucalyptus camaldulensis against Leishmania major. Journal of parasitic diseases. 2015;39:18-21.

160. Mahmoudvand H, Tavakoli R, Sharififar F, Minaie K, Ezatpour B, Jahanbakhsh S, et al. Leishmanicidal and cytotoxic activities of Nigella sativa and its active principle, thymoquinone. Pharmaceutical Biology. 2015;53(7):1052-7.

161. Mahmoudvand H, Ezzatkhan F, Sharififar F, **Sharifi I**, Dezaki ES. Antileishmanial and cytotoxic effects of essential oil and methanolic extract of Myrtus communis L. The Korean journal of parasitology. 2015;53(1):21.

162. GHASEMI NAP, **SHARIFI I**, KAZEMI B, BABAEI Z, BANDEHPUR M, SALARI S, et al. USING PRIMARY ANTIBODIES AGAINST THE LINEAR EPITOPES GPI12 PROTEIN INSTEAD OF COMPLETE PROTEIN IN LEISHMANIA MAJOR USING WESTERN BLOT TECHNIQUE. 2015.

163. Daie Parizi MH, Karvar M, **Sharifi I**, Bahrampour A, Heshmat Khah A, Rahnema Z, et al. The topical treatment of anthroponotic cutaneous leishmaniasis with the tincture of thioxolone plus benzoxonium chloride (T hio-B en) along with cryotherapy: a single-blind randomized clinical trial. Dermatologic Therapy. 2015;28(3):140-6.

164. Bamorovat M, **Sharifi I**, Dabiri S, Mohammadi MA, Harandi MF, Mohebbi M, et al. Leishmania tropica in stray dogs in southeast Iran. Iranian journal of public health. 2015;44(10):1359.

165. Bahreini M, Bolorizadeh M, Dabiri S, **Sharifi I**. Evaluation of organelle changes in promastigotes of unresponsive leishmania tropica to meglumine antimoniate in comparison with sensitive and standard isolates by electron microscopy. Indian Journal of Dermatology. 2015;60(3):321.

166. Aflatoonian MR, **Sharifi I**, Aflatoonian B, Divsalar K. Changes in the pattern of opium addiction in Bam after the earthquake. *Report of Health Care*. 2015;1(3):104-8.
167. Abbaszadeh-Afshar MJ, Mohebbali M, **Sharifi I**, Akhoundi B, Aflatoonian MR, Bahreini MS, et al. Seroepidemiological survey of Visceral leishmaniasis among nomadic tribes of Kerman Province, Southeastern Iran: An observational study for implication to health policy. *Journal of Biostatistics and Epidemiology*. 2015;1(3/4):105-11.
168. Yazdani R, **Sharifi I**, Bamorovat M, Mohammadi MA. Human linguatulososis caused by *Linguatula serrata* in the city of Kerman, South-eastern Iran-case report. *Iranian journal of parasitology*. 2014;9(2):282.
169. Seyed N, Taheri T, Vauchy C, Dosset M, Godet Y, Eslamifar A, et al. Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from *Leishmania major* related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine. *PLoS One*. 2014;9(10):e108848.
170. Radfar MH, Zarandi MB, Bamorovat M, Kheirandish R, **Sharifi I**. Hematological, biochemical and pathological findings in goats naturally infection with *Cysticercus tenuicollis*. *Journal of Parasitic Diseases*. 2014;38:68-72.
171. Mehdi B, Iraj S, Mohammad Ali M, Majid Fasihi H, Mehdi M, Reza Malekpour A, et al. Canine visceral leishmaniasis in Kerman, southeast of Iran: a seroepidemiological, histopathological and molecular study. 2014.
172. Mahshid M, Baharak A, Iraj S, Sina K, Javad K, Mehdi B. Seroprevalence of canine visceral leishmaniasis in southeast of Iran. *Journal of parasitic diseases*. 2014;38:218-22.
173. Mahmoudvand H, Sharififar F, **Sharifi I**, Ezatpour B, Harandi MF, Makki MS, et al. In vitro inhibitory effect of *Berberis vulgaris* (Berberidaceae) and its main component, berberine against different *Leishmania* species. *Iranian journal of parasitology*. 2014;9(1):28.
174. Mahmoudvand H, Sharififar F, Rahmat MS, Tavakoli R, Dezaki ES, Jahanbakhsh S, et al. Evaluation of antileishmanial activity and cytotoxicity of the extracts of *Berberis vulgaris* and *Nigella sativa* against *Leishmania tropica*. *Journal of vector borne diseases*. 2014;51(4):294-9.
175. Mahmoudvand H, **Sharifi I**, Fasihi Harandi M, Shokohi M, Shakibaie M, Rezaei Rabani T, et al. Anti-leishmania effects of methotrexate (MTX) alone and in combination with meglumine antimoniate (MA) against Iranian isolate of sensitive and MA-resistant *Leishmania tropica*: An invitro assay. *Asian Pacific J Trop Med*. 2014;4:412-20.
176. Mahmoudvand H, Shakibaie M, Tavakoli R, Jahanbakhsh S, **Sharifi I**. In vitro study of leishmanicidal activity of biogenic selenium nanoparticles against Iranian isolate of

sensitive and glucantime-resistant *Leishmania tropica*. Iranian journal of parasitology. 2014;9(4):452.

177. Khazaeli P, **Sharifi I**, Talebian E, Heravi G, Moazeni E, Mostafavi M. Anti-leishmanial effect of itraconazole niosome on in vitro susceptibility of *Leishmania tropica*. Environmental toxicology and pharmacology. 2014;38(1):205-11.

178. Hosseininassab A, **Sharifi I**, Daei MH, Zarean M, Dadkhah M. Causes of pediatric visceral leishmaniasis in southeastern Iran. Iranian Journal of Parasitology. 2014;9(4):584.

179. Ghatee MA, **Sharifi I**, Kuhls K, Kanannejad Z, Harandi MF, de Almeida ME, et al. Heterogeneity of the internal transcribed spacer region in *Leishmania tropica* isolates from southern Iran. Experimental parasitology. 2014;144:44-51.

180. Ghaffari D, Hakimi Parizi M, Yaghoobi Ershadi MR, **Sharifi I**, Akhavan AA. A survey of reservoir hosts in two foci of cutaneous leishmaniasis in Kerman province, southeast of Iran. Journal of parasitic diseases. 2014;38:245-9.

181. Barati M, **Sharifi I**, Sharififar F, Hakimi Parizi M, Shokri A. Anti-leishmanial activity of *Gossypium hirsutum* L., *Ferula assa-foetida* L. and *Artemisia aucheri* Boiss. Extracts by colorimetric assay. Anti-Infective Agents. 2014;12(2):159-64.

182. Bamorovat M, Zarandi MB, Mostafavi M, Kheirandish R, **Sharifi I**, Radfar MH. The prevalence of *Linguatula serrata* nymphs in mesenteric and mediastinal lymph nodes in one-humped camels (*Camelus dromedarius*) slaughtered in Rafsanjan slaughterhouse, Iran. Journal of Parasitic Diseases. 2014;38:374-7.

183. Bamorovat M, **Sharifi I**, Mohammadi MA, Harandi MF, Mohebbi M, Afshar RM, et al. Canine visceral leishmaniasis in Kerman, southeast of Iran: a seroepidemiological, histopathological and molecular study. Iranian journal of parasitology. 2014;9(3):342.

184. Ali H, Iraj S, Mohammad Hossein D, Mehdi Z, Mahsa D. Causes of pediatric visceral leishmaniasis in southeastern Iran. 2014.

185. Aghaei AA, Rassi Y, **Sharifi I**, Vatandoost H, Mollaie H, Oshaghi M, et al. First report on natural *Leishmania* infection of *Phlebotomus sergenti* due *Leishmania tropica* by high resolution melting curve method in South-eastern Iran. Asian Pacific journal of tropical medicine. 2014;7(2):93-6.

186. Aflatoonian MR, **Sharifi I**, Hakimi Parizi M, Fekri AR, Aflatoonian B, Sharifi M, et al. A prospective cohort study of cutaneous leishmaniasis risk and opium addiction in south eastern Iran. PloS one. 2014;9(2):e89043.

187. Aflatoonian M, **Sharifi I**, Nadim A, Aflatoonian B. Comparison of the period prevalence of urban cutaneous leishmaniasis (CL) in Bam in two time periods of 1990-1992 and 2010-2012. 2014.
188. Aflatoonian M, **Sharifi I**, Aflatoonian B. The effects of prevention knowledge compared to the improvement of housing conditions in control of anthroponotic cutaneous leishmaniasis: a natural experience of earthquake in Bam/Iran. *Journal of Kerman University of Medical Sciences*. 2014;21(3):247-58.
189. Seyed N, Taheri T, Vauchy C, Dosset M, **Sharifi I**, Rohrlisch P, et al., editors. Rationally designed DNA construct encoding MHC class I restricted epitopes derived from *Leishmania* major proteins successfully provokes cytotoxic CD8 T cell responses in Balb/c mice. *Front Immunol Conference Abstract: 15th International Congress of Immunology (ICI)* doi: 103389/conf.fimmu; 2013.
190. Riabi TR, **Sharifi I**, Mohammadi AM, Khamesipour A, Parizi MH. Evaluation of a possible synergistic effect of meglumine antimoniate with paromomycin, miltefosine or allopurinol on in vitro susceptibility of *Leishmania tropica* resistant isolate. *Iranian Journal of Parasitology*. 2013;8(3):396.
191. Noazin S, Shirzadi MR, Kermanizadeh A, Yaghoobi-Ershadi M-R, **Sharifi I**. Effect of large-scale installation of deltamethrin-impregnated screens and curtains in Bam, a major focus of anthroponotic cutaneous leishmaniasis in Iran. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2013;107(7):444-50.
192. Khosravi A, **Sharifi I**, Dortaj E, Afshar AA, Mostafavi M. The present status of cutaneous leishmaniasis in a recently emerged focus in south-west of Kerman Province, Iran. *Iranian Journal of Public Health*. 2013;42(2):182.
193. Ghatee MA, **Sharifi I**, Haghdoost AA, Kanannejad Z, Taabody Z, Hatam G, et al. Spatial correlations of population and ecological factors with distribution of visceral leishmaniasis cases in southwestern Iran. *Journal of Vector Borne Diseases*. 2013;50(3):179-87.
194. Ghatee M, **Sharifi I**, Mirhendi H, Kanannejad Z, Hatam G. Investigation of double-band electrophoretic pattern of ITS-rDNA region in Iranian isolates of *Leishmania tropica*. *Iranian journal of parasitology*. 2013;8(2):264.
195. Aflatoonian MR, **Sharifi I**, Poursmaelian S, Hakimi-Parizi M, Ziaali N. The emergence of anthroponotic cutaneous leishmaniasis following the earthquake in southern villages of Bam district, southeastern Iran, 2010. *Journal of Arthropod-Borne Diseases*. 2013;7(1):8.

196. Abbas AA, Hassan V, Iraj S, Yavar R, Reza AM, Ali OM, et al. First determination of impact and outcome indicators following indoor residual spraying (IRS) with deltamethrin in a new focus of anthroponotic cutaneous leishmaniasis (ACL) in Iran. *Asian Pacific Journal of Tropical Disease*. 2013;3(1):5-9.
197. Shokri A, **Sharifi I**, Khamesipour A, Nakhaee N, Fasihi Harandi M, Nosratabadi J, et al. The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of *Leishmania tropica* to meglumine antimoniate. *Parasitology research*. 2012;110:1113-7.
198. Sharifi F, **Sharifi I**, Zarean M, Parizi MH, Aflatoonian M, Harandi MF, et al. Spatial distribution and molecular identification of *Leishmania* species from endemic foci of south-eastern Iran. *Iranian journal of parasitology*. 2012;7(1):45.
199. Mirzaei M, **Sharifi I**, Poursmaelian S. A new focus of anthroponotic cutaneous leishmaniasis and identification of parasite species by nested PCR in Jiroft, Iran. *Comparative Clinical Pathology*. 2012;21:1071-5.
200. Mahmoudvand H, Farivar L, **Sharifi I**, Harandi MF, Moazed V, Jahanbakhsh S, et al. Fatal case of *Plasmodium vivax* malaria in a splenectomized patient. *Iranian Journal of Parasitology*. 2012;7(3):99.
201. Khatami A, Rahshenas M, Bahrami M, Ghoorchi M, Eskandari S, **Sharifi I**. Miltefosine in treatment of cutaneous leishmaniasis: a randomized controlled trial: P31. *Br J Dermatol*. 2012;167(167).
202. Asgari Nezhad H, Mirzaie M, **Sharifi I**, Zarean M, Norouzi M. The prevalence of cutaneous leishmaniasis in school children in southwestern Iran, 2009. *Comparative Clinical Pathology*. 2012;21:1065-9.
203. Asadi M, Pardakhty A, Moshafi M, **Sharifi I**. Preparation and in vivo administration of paromomycin niosomes in balb/c mice. *Research in Pharmaceutical Sciences*. 2012;7(5):373.
204. Aflatonian M, Akhtardanesh B, Sharifi E, Mostavafi M, Aflatonian B, Khalili M, et al. Seroepidemiology of canine visceral leishmaniasis in Kerman City, 2011. *Journal of Kerman University of Medical Sciences*. 2012;19(3):531-9.
205. **Sharifi I**, Poursmaelian S, Aflatoonian MR, Ardakani RF, Mirzaei M, Fekri AR, et al. Emergence of a new focus of anthroponotic cutaneous leishmaniasis due to *Leishmania tropica* in rural communities of Bam district after the earthquake, Iran. *Tropical Medicine & International Health*. 2011;16(4):510-3.
206. **Sharifi I**, Pour R, Kazemi B, Parizi M, editors. Resistant isolates of anthroponotic cutaneous leishmaniasis to glucantime and genetic diversity of *Leishmania tropica* MDR1

gene in Bam, south-eastern Iran. TROPICAL MEDICINE & INTERNATIONAL HEALTH; 2011: WILEY-BLACKWELL COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA.

207. **Sharifi I**, Nakhaei N, Aflatoonian M, Parizi MH, Fekri A, Safizadeh H, et al. Cutaneous leishmaniasis in Bam: A comparative evaluation of pre-and post-earthquake years (1999–2008). Iranian Journal of Public Health. 2011;40(2):49.

208. Seyed N, Zahedifard F, Safaiyan S, Gholami E, Doustdari F, Azadmanesh K, et al. In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response. Plos neglected tropical diseases. 2011;5(9):e1295.

209. Pour R, **Sharifi I**, Kazemi B, Zarean M. Identification of nonresponsive isolates to Glucantime in patients with cutaneous Leishmaniasis in Bam. Journal of Kerman University of Medical Sciences. 2011;18(4):123-34.

210. Poresmaeliyan S, Mirzaei M, Sharifi E, Zarean M. The prevalence of cutaneous leishmaniasis in the city and suburb of Mohammadabad, Jiroft district and identification of parasite species by Nested-PCR, 2008. Journal of Kerman University of Medical Sciences. 2011;18(3):218-27.

211. Mohebbali M, Edrissian GH, Shirzadi MR, Akhoundi B, Hajjarian H, Zarei Z, et al. An observational study on the current distribution of visceral leishmaniasis in different geographical zones of Iran and implication to health policy. Travel medicine and infectious disease. 2011;9(2):67-74.

212. Mahmoudvand H, **Sharifi I**, Mohebbali M, Keshavarz H, Hajjarian H, Akhoundi B, et al., editors. A new endemic focus of visceral leishmaniasis (Kala-azar) in Kerman province, southeast of Iran. TROPICAL MEDICINE & INTERNATIONAL HEALTH; 2011: WILEY-BLACKWELL COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA.

213. Mahmoudvand H, **Sharifi I**, Farivar L, Moazed V, Harandi M, Jahanbakhsh S, et al., editors. Severe Plasmodium vivax malaria in splenectomized patient. TROPICAL MEDICINE & INTERNATIONAL HEALTH; 2011: WILEY-BLACKWELL COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA.

214. Mahmoudvand H, Mohebbali M, **Sharifi I**, Keshavarz H, Hajjarian H, Akhoundi B, et al. Epidemiological aspects of visceral leishmaniasis in Baft district, Kerman Province, Southeast of Iran. Iranian journal of parasitology. 2011;6(1):1.

215. Khosravi A, **Sharifi I**, Barati M, Zarean M, Hakimi-Parizi M. Anti-leishmanial effect of nanosilver solutions on *Leishmania tropica* promastigotes by in-vitro assay. *Zahedan Journal of Research in Medical Sciences*. 2011;13(7).
216. Khamesipour A, KHATAMI A, **Sharifi I**, Bahrami M, Javadi A, ESKANDARI SE, et al. Comparison of the efficacy of weekly vs. twice a week intralesional injections of meglumine antimoniate in the treatment of anthroponotic cutaneous leishmaniasis: a randomized clinical trial. 2011.
217. Harandi MF, Moazezi S, Saba M, Grimm F, Kamyabi H, Sheikhzadeh F, et al. Sonographical and serological survey of human cystic echinococcosis and analysis of risk factors associated with seroconversion in rural communities of Kerman, Iran. *Zoonoses and public health*. 2011;58(8):582-8.
218. Ghatei M, **Sharifi I**, Nejad Z, Hatam G, editors. False-positive reactivity of latex agglutination test for kala-azar (Katex) without urine sample boiling in auto-immune patients. *TROPICAL MEDICINE & INTERNATIONAL HEALTH*; 2011: WILEY-BLACKWELL COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA.
219. Afshar AA, Rassi Y, **Sharifi I**, Abai M, Oshaghi M, Yaghoobi-Ershadi M, et al. Susceptibility status of *Phlebotomus papatasi* and *P. sergenti* (Diptera: Psychodidae) to DDT and deltamethrin in a focus of cutaneous leishmaniasis after earthquake strike in Bam, Iran. *Iranian journal of arthropod-borne diseases*. 2011;5(2):32.
220. Aflatoonian M, **Sharifi I**. The epidemiology of cutaneous leishmaniasis in the city and suburb of Bam in 2010: active case-finding, treatment and health education of the school children. 2011.
221. **Sharifi I**, Ranjbar L, Aflatoonian M, Abbasi R. To Evaluate the Costs of Prevention on Incidence of Cutaneous Leishmaniasis due of Earthquake in Bam. *مجله تخصصی اپیدمیولوژی ایران*. ۲۰۱۰; ۶: ۱-۲.
222. **Sharifi I**, Fekri AR, Aflatoonian MR, Khamesipour A, Mahboudi F, Dowlati Y, et al. Leishmaniasis recidivans among school children in Bam, South-east Iran, 1994–2006. *International journal of dermatology*. 2010;49(5):557-61.
223. Pouresmaeilian S, **Sharifi I**, Aflatoniyani M, Fotuhi Ardakani R, Mirzaei M, Barati M. A new focus of anthroponotic cutaneous leishmaniasis in Dehbakry region of Bam district, southeastern Iran 2008. *Journal of Kerman University of Medical Sciences*. 2010;16(1):15-24.
224. Barati M, Sharifi L, Sharififar F. Antileishmanial activity of *Artemisia aucheri*, *Ferula asafoetida* and *Gossypium hirsutum* extracts on *Leishmania major* promastigotes in vitro. 2010.

225. Barati M, **Sharifi I**, SHarififar F. In vitro evaluation of anti-leishmanial activities of *Zataria Multiflora* Boiss, *Peganum Harmala* and *Myrtus Communis* by colorimetric assay. *Journal of Kerman University of Medical Sciences*. 2010;16(1):32-42.
226. Ali K, Alireza K, Iraj S, Mahdie B, Amir J, Seyed Ebrahim E, et al. Comparison of the efficacy of weekly vs. twice a week intralesional injections of meglumine antimoniate in the treatment of anthroponotic cutaneous leishmaniasis: a randomized clinical trial. 2010.
227. Aflatoonian M, **Sharifi I**. Prevalence rate of cutaneous leishmaniasis in Bam district during 20 years (1988-2007). *Journal of Kerman University of Medical Sciences*. 2010;17(2):297-306.
228. Aflatoonian M, **Sharifi I**, Abbasi R, Ranjbar L. To evaluate the costs of prevention on incidence of Cutaneous leishmaniasis due of earthquake in Bam. 2010.
229. Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasser K, Modabber F, et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis—A meta-analysis. *Vaccine*. 2009;27(35):4747-53.
230. Fazaeli A, Fouladi B, **Sharifi I**. Emergence of cutaneous leishmaniasis in a border area at south-east of Iran: an epidemiological survey. *Journal of vector borne diseases*. 2009;46(1):36.
231. Aflatonian M, **Sharifi I**, Fekri A. Evaluation of the cost-effectiveness of cutaneous leishmaniasis treatment after the earthquake in Bam. *Journal of Kerman University of Medical Sciences*. 2009;16(2):365-73.
232. Tashakori M, Al-Jawabreh A, Alimohammadian M, **Sharifi I**, Rezaeian M, MohseniMoqhadam F. Detection of Polymorphism within *L. major* isolates Collected from Iranian Patients Suffering from Cutaneous Leishmaniasis by Microsatellite Markers. *Journal of Rafsanjan University of Medical Sciences*. 2008;7(1):21-30.
233. **Sharifi I**, Aflatoonian M, Fekri A. An epidemic of cutaneous leishmaniasis in Baft district in Kerman Province and its probable causative risk factors. *Iranian Journal of Epidemiology*. 2008;4(1):53-8.
234. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasser K, et al. First generation leishmaniasis vaccines: a review of field efficacy trials. *Vaccine*. 2008;26(52):6759-67.
235. Fotohiardakani R, Harandi Fasihi M, Soliman Banaei S, Kamyabi H, Atapour M, **Sharifi I**. Epidemiology of *Cryptosporidium* infection of cattle in Kerman/Iran and molecular genotyping of some isolates. *Journal of Kerman University of Medical Sciences*. 2008;15(2):313-20.

236. Fazaeli A, Fouladi B, HASHEMI SS, **Sharifi I**. Clinical features of cutaneous leishmaniasis and direct pcrbased identification of parasite species in a new focus in Southeast of Iran. 2008.
237. Barati M, **Sharifi I**, Daie Parizi M, Fasihi Harandi M. Bacterial infections in children with visceral leishmaniasis: observations made in Kerman province, southern Iran, between 1997 and 2007. *Annals of Tropical Medicine & Parasitology*. 2008;102(7):635-41.
238. Barati M, Daie Parizi M, **Sharifi I**. Epidemiological and Clinical aspects of kala-azar in hospitalized children of Kerman province, during 1991-2006. *Journal of Kerman University of Medical Sciences*. 2008;15(4):148-55.
239. Aflatonian M, **Sharifi I**. Epidemiology of Cutaneous leishmaniasis and it's relationship with blood groups in Bam, 2007. *Journal of Kerman University of Medical Sciences*. 2008;15(2):295-303.
240. Mirzaie M, Nosratabadi SJ, Derakhshanfar A, **Sharifi I**. Antileishmanial activity of Peganum harmala extract on the in vitro growth of Leishmania major promastigotes in comparison to a trivalent antimony drug. *Veterinarski arhiv*. 2007;77(4):365-75.
241. Mirzaie M, Nosratabadi SJ, Derakhshanfar A, **Sharifi I**. Protulišmanijski učinak iscrpka biljke Peganum harmala na in vitro rast promastigota Leishmania major u odnosu na trovalentne pripravke antimona. *Veterinarski arhiv*. 2007;77(4):365-75.
242. Fouladi B, **Sharifi I**, Shahri SMH, Moradgholi H, Sarabandi A, Ebrahimzadeh A, et al. Evaluation of a direct PCR in comparison with routine microscopy and In vitro culture for diagnosis of cutaneous leishmaniasis. *Zahedan Journal of Research in Medical Sciences*. 2007;9(3).
243. Fazaeli A, Fuladi B, Shahri MH, **Sharifi I**. Evaluation of a direct PCR in comparison with routine microscopy and in vitro culture for diagnosis of cutaneous leishmaniasis. *Iranian Journal of Public Health*. 2007;36(Supple 2):1-2.
244. Aflatoonian M, **Sharifi I**. Prevalence of cutaneous leishmaniasis in school children in Bam and Barawat/Iran in 2006. *Journal of Kerman University of Medical Sciences*. 2007;14(4):82-9.
245. Ebrahimzadeh A, Polshakan M, Qureshi M, **Sharifi I**. Reliable DNA extraction on historical malaria negative smears conducted to nested PCR in south-east of Iran. 2006.
246. AFLATOUNIAN M, **SHARIFI I**. FREQUENCY OF CUTANEOUS LEISHMANIASIS AMONG PATIENTS REFERRED TO THE CENTER FOR DISEASE CONTROL IN BAM DISTRICT, 1999-2003. 2006.

247. Aflatonian M, **Sharifi I**. Frequency of cutaneous leishmaniasis among patients referred to the center for disease control in Bam district, 1999-2003. *Journal of Rafsanjan University of Medical Sciences*. 2006;5(2):123-8.
248. Vatandoost H, Mashayekhi M, Abaie M, Aflatoonian M, Hanafi-Bojd A, **Sharifi I**. Monitoring of insecticides resistance in main malaria vectors in a malarious area of Kahnooj district, Kerman province, southeastern Iran. *Journal of vector borne diseases*. 2005;42(3):100-8.
249. MAHMOUDI M, FEKRI A, HAGHPARAST A, NOSRATABADI S, **Sharifi I**. Evaluation of meglumine antimonate therapy in cutaneous leishmaniasis: Comparison of in vitro sensitivity of *Leishmania tropica* isolates from patients treated with drug with clinical response. 2003.
250. Aghasi M, **Sharifi I**. Survey of the fauna and monthly activity of the sandfly as the vectors of the cutaneous leishmaniasis in the City of Bam. 2003.
251. Basiri E, Ardehali S, **SHARIFI I**, KAMALI E, HABIB AM, Ghaderi A. Production and partial characterization of monoclonal antibodies to *Leishmania*. 2002.
252. **Sharifi I**, Zarezadeh M, Fekri A. Identification of cutaneous leishmaniasis species by immunofluorescence examination using monoclonal antibodies in Kerman and Rafsanjan Cities, South-Eastern Iran. 2001.
253. ZAMANI G, **Sharifi I**, HOLAKOVEI K, NADIM A. DESIGNING GIS FOR CONTROL AND MANAGEMENT OF MALARIA IN KAHNUJ. 2000.
254. NASIRI KM, **Sharifi I**, KHAJEH KAM, Pourlashkari M. Prevalence of infectious skin diseases in the central prison of Kerman. 2000.
255. Ardehali S, Moattari A, Hatam G, Hosseini S, **Sharifi I**. Characterization of *Leishmania* isolated in Iran: 1. Serotyping with species specific monoclonal antibodies. *Acta tropica*. 2000;75(3):301-7.
256. Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Ghassemi RL, et al. A randomised, double-blind, controlled trial of a killed *L. major* vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. *Vaccine*. 1999;17(5):466-72.
257. Ardehali S, Moattari A, **Sharifi I**. Determination of the Characteristics of *Leishmania* Parasite Using Monoclonal Antibodies Isolated in Iran. *Research in Medicine*. 1999;23(4):233-8.
258. **Sharifi I**, FeKri AR, Aflatonian M-R, Khamesipour A, Nadim A, Mousavi M-RA, et al. Randomised vaccine trial of single dose of killed *Leishmania major* plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. *The Lancet*. 1998;351(9115):1540-3.

259. **Sharifi I**, Fekri A, Aflatonian M, Nadim A, Nikian Y, Kamesipour A. Cutaneous leishmaniasis in primary school children in the south-eastern Iranian city of Bam, 1994-95. *Bulletin of the World Health Organization*. 1998;76(3):289.
260. **Sharifi I**. The prevalence, incidence and reinfection rate of *Giardia lamblia* in primary schoolchildren in rural suburb of Kerman city in southern Iran. 1998.
261. Iraj S. < The> prevalence, incidence and reinfection rate of *Giardia lamblia* in primary school children in rural suburb of Kerman city in southern Iran. 1998.
262. **Sharifi I**, Keshavarz H. The prevalence of intestinal parasites in Afghan refugees in Kerman city, Iran. 1997.
263. **Sharifi I**, Ardehali S, Motazedian H, Aflatonian M, Fekri A, Ahmadi MM. Identification and characterization of *Leishmania* isolates in school children in Bam, south-eastern Iran. 1997.
264. Iraj S, Hossein K. < The> prevalence of intestinal parasites in afghan refugees in Kerman City, Iran. 1997.
265. **Sharifi I**, Zia-Ali N. The present status and intensity of *Echinococcus granulosus* infection in 391 stray dogs in rural and urban areas of the city of Kerman, Iran. *Iranian Journal of Public Health*. 1996;25(3-4):13-20.
266. **Sharifi I**, Daneshvar H, Ziyaali N, Fasihi-Harandi M, Nikiyan Y, Ebrahimi A, et al. Evaluation of a control program on hydatid cyst in the city of Kerman. *Journal of kerman university of Medical Sciences*. 1996;3(2):168-74.
267. **Sharifi I**, Daneshvar H. The prevalence of visceral leishmaniasis in suspected canine reservoirs in southeastern Iran. *Iranian J Basic Med Sci*. 1996;21:130-4.
268. **Sharifi I**. The seasonal prevalence of hydatid cyst in slaughter-house of the city of Kerman. *Iranian Journal of Public Health*. 1996;25(3-4):39-46.
269. **Sharifi I**, Arab N. The role of health education in prevention of *Giardia lamblia* infection in primary schools in a Suburb Area of Kerman city. *Journal of Kerman University of Medical Sciences*. 1995;2(2):170-6.
270. Tasbiti A-Z, **Sharifi I**. THE PREVALENCE OF INTESTINAL HELMINTHS IN STRAY DOGS IN KERMAN CITY. *Iranian Journal of Public Health*. 1994;23:1-2.
271. **Sharifi I**, Tasbiti AH-Z. The prevalence of intestinal helminths in stray dogs in Kerman city. 1994.
272. **Sharifi I**, Tasbiti A. Helminth parasites of stray dogs in Kerman. 1994.

273. **Sharifi I**, Khatami M, Tahmors-Kermani E. Prevalence of *Trichomonas Vaginalis* in women referred to Vali-Asr polyclinic and the health center number 3 in Sirjan city. *Journal of Kerman University of Medical Sciences*. 1994;1(3):125-34.
274. **Sharifi I**. Comparative study between efficacy of metronidazole and furazolidone in 7 to 11 year old children with giardiasis. 1992.
275. Iraj S. Comparative study between efficacy of metronidazole and furazolidone in 7 to 11 year old children with giardiasis. 1992.
276. **Sharifi I**, Nollen P. The effect of six herbicides on the longevity of *Schistosoma mansoni* miracidia. 1981.
277. **Sharifi I**, Nollen P. The effect of six herbicides on the longevity of *Schistosoma mansoni* miracidia [Sutan, Lasso, Vernam, Eptam, Ro-Neet and 2, 4, 5,-T]. *Transactions of the Illinois State Academy of Science (USA)*. 1981.
278. **Sharifi I**. The longevity of *Schistosoma mansoni* miracidia in fresh and one-week-old solutions of seven herbicides: Western Illinois University; 1977.
279. Stermitz F, Lowry W, Ubben E, **Sharifi I**. 1, 6-Di-3-nitropropanoyl- β -D-glucopyranoside from *Astragalus cibarius*. *Phytochemistry*. 1972;11(12):3525-7.
280. Mirzaee H, Salehinia H, Mohammadi A, **Sharifi I**, Mirzaeian H, Mirzaee H, et al. Prevalence of overweight and obesity and its related demographic factors in people older than 30 years living in the Frieden city of Isfahan in 2013. *Journal of Sabzevar University of Medical Sciences*. 1970;21(6):968-76.

2. Authors' citation

- 1-Sharifi I, Alahi R; prevalence and clinical signs and symptoms of *Giardia lamblia* in rural communities of Kerman and importance of multiple stool exams. *Journal of Teb & Tazkieh*, 15: 59-66, 1995(Farsi).
- 2-Sharifi I: Comparative study between efficacy of metronidazole and furazolidone in 7 to 11 year-old children with giardiasis. *Med J of Islamic Rep of Iran*.6 (2): 105-108, 1992.
- 3-Sharifi I, Taddion Tahmasbi S: The prevalence of *Trichomonas vaginalis* in women with leukorrhea in Kerman city, *Nabz Journal* 6(4): 7-14, 1993 (Farsi).
- 4-Sharifi I, et al: Malaria in Kerman province between 1983-1993. *Drug and Treatment J*, 122:22-28, 1993(Farsi).

- 5-Sharifi I, Hadizadeh A: The prevalence of intestinal helminthes in stray dogs in Kerman city. Iranian J. Public Health 23 (1-3): 13-23, 1993(Farsi).
- 6-Sharifi I, Khatami M, Tahmors Kermani H: The prevalence of Trichomonas vaginalis in referral women in Sirjan city and comparison of direct smear with culture method. Med Journal of Kerman Uni of Med Sci, 3: 125-132, 1994(Farsi).
- 7-Sharifi I, Nasser A: The role of health education in prevention of Giardia lamblia infections in primary schoolchildren in suburbs of Kerman city. Part I. Medical Journal of Kerman Uni Med SCI (7): 23-28, 1995.
- 8-Sharifi I, Keshavars H: The effect of health education in prevention of Giardia lamblia infection in 120 households in rural suburbs of Kerman city. Part II. Journal of Tropical Medicine and Infectious Diseases (8): 32-38, 1998.
- 9-Sharifi I, Zia-Ali N: The present status and intensity of Echinococcus granulosus infection in 391 stray dogs in rural and urban areas of the city of Kerman. Iranian J. of Public Health 25(3-40): 13-20, 1996.
- 10- Sharifi I et al: Evaluation of a control program on hydatid cyst in the city of Kerman. Med J of Kerman Uni of Med Sci, No.8: 7-14, 1996(Farsi).
- 11-Sharifi I et al: Keshvarz H: The prevalence of intestinal parasite in Afghan refugees in Kerman province. Hamdad Medicus, Vol XL (4); 100-104, 1997.
- 12-Shamsadini S, Sharifi I: Chronic granulomatous macrocheilitis due to lupoid leishmaniasis in Bam, Iran 9in press in Annals of Saudi Medicine, letter no. 19980085, 2 Aug. 1998).
- 13-Kalantari K. Ameri f, Sharifi I: Enterobius vermicularis in nursery schools. Medical Journal of Sabesevar University. 2 (3): 36-42, 1995(Farsi)
- 14-Sharifi I: The seasonal prevalence of hydatid cyst in slaughter-house of the city of Kerman. Iranian J. Publ Health, 25(3-4): 39-46, 1996.

- 15-Sharifi I: The prevalence, incidence and reinfection rate of *Giardia lamblia* in primary school children in rural suburbs of Kerman city in south-eastern Iran. *Hamdard Medicus*, Vol XLI (2): 76-79, 1998.
- 16-Ardehali S, Sharifi I et al: Identification of *Leishmania* isolates in Iran using monoclonal antibodies. *Research in Medicine*, 23 (4), 1999(Farsi)
- 17-Zamani G, Sharifi I, Holakove: K, Nadim A: Designing GIS for control and management of malaria in Kahnouj. *Hakim Journal* 3(1): 57-68, 2000 (Farsi).
- 18-Shamsadini S, Sharifi I et al. Prevalence of cutaneous disease in Kerman central prison. *Skin Diseases* 4(1): 19-25, 2000 (Farsi).
- 19-Mahmoodi M, Sharifi I, et al: Cutaneous leishmaniasis resistance to sodium stibogluconate: Comparing sensitivity of *Leishmania* isolated from patients to drug in vitro and in vivo. *Journal of Semnan Uni of Med Sci*, 4(3-4): 143-150, 2003 (Farsi).
- 20-Aghasi M, Sharifi I: Survey of the Fauna and monthly activating of the sandfly as the vectors of the cutaneous leishmaniasis in the city of Bam. *Journal of Kerman University of Medical Sciences*, 10(2): 85-91, 2003 (Farsi).
- 21-Sharifi I: The effect of six herbicides on the longevity of *Schistosoma mansoni* miracidia. *Transactions of the Illinois State Academy of Science*, 74(1): 91-99 1981.

3. Abstracts

1-Sharifi I: the effect of sewage treatment processes in the viability of *Taenia taeniaeformis* ova and embryonation of *Toxocara canis* eggs. Abstract of the first Congress of Parasitic Disease in Iran. Guilan Uni of Med Sci 11-13 Dec, 1990, p 77 (Farsi).

2-Arab N, Sharifi I, Keshavarz H: 2nd report of *Moniliformis moniliformis* in Iran Abstracts of the First Congress of Paractic Disease in Iran. Guilan Uni of Sci 11-13 Dec, 1990, p 144 (Farsi).

3-Sharifi I: The present status of malaria in Kerman provice. First National Congress of Malaria, Feb 2-26, 1992. Abstracts p 14, Zahedan Uni of Msd Sci (Farsi).

4-Sharifi I, Zareh Z, M Fekri AR: Identification of cutaneous leishmaniasis in Kerman and Rafsanjan by indirect fluorescent antibody examination using monoclonal antibodies. The Second Congress of Parasitic Disease in Iran. Tehran Uni of Medi, Sci, Sept 27-30, p 228, 1997(Farsi).

5-Aradehali S, Sharifi I et al: Identification of *Leishmania* isolates in Iran. The Second Congress of Parasites in Iran. Tehran Uni of Med. Sci, Sept 27-30, p 47, 1997(Farsi).

6-Barahoei M, Sharifi I: The prevalence of intestinal parasites in urban and rural areas of Zabole, Zahedan Provincs Diseases. The Second Congress of Parasitic Diasease in Iran. Tehran Uni of Med, Sci, Sept 27-30, p 218, 1997 (Farsi).

7-Sharifi I et al: Evaluation of a control program on hydatid cyst in the city of Kerman. 2nd National Congress on Parasitic Diseases. Oct. 19-22, 1997 Tehran Iran, p. 194.

8-Sharifi I et al: Field trial of Killed *Leishmania major* against *Leishmania tropica* in Bam 2nd National Congress of Parasitic Disases. Oct 19-22, 1997, Tehran Iran p.98.

9-Creta Maris Hotel, Hersonissos, Crete Greece, P.113.

10-Mahmoodi M, Sharifi I et al; T-cell responses in cutaneous leishmaniasis: Comparison of nonhealing patients and cases with Previous positive leishmanin skin test with Cured individuals of the disease .World Leish 2,May 20-24,2001, Creta Maris Hotel, Hersonissos, Crete Greece. P.87.

11-Mahmoodi M, Sharifi I et al: Immune responses measured in human volunteers vaccinated with autoclaved *Leishmania major* plus BCG .World Leish 2, May 20-24, 2001, Creta Maris Hotel, Hersonissos, Crete Greece. P.90.

12-Khamesipour A, Sharifi I et al: Phase III efficacy field trial of multiple doses of ALM vaccine mixed with BCG in children in zoonotic cutaneous leishmaniasis (ZCL) endemic area World Leish 2, May 20-24, 2001, Creta Maris Hotel, Hersonissos, Crete Greece. P.90.

13- Sharifi, M. R. Aflatonian. A.H. Nadim: Filed trial on ALM vaccine efficacy against anthroponotic cutaneous leishmaniasis in 6, 10 year old children in Ban Iran. Clinical trials of killed leishmania major vaccine, 96. 4. 15-16 Apr Amman-Jordan.

14-I. Sharifi I, A.R.Fekri, M.R. Aflatonian, and A. Nadim: Double blind randomized filed trial of ALM. Vaccine of 33fficacy against ACL in Bam. Iran. First world on leishmaniasis, 97. 5. 5-9 May, Istanbul, Turkey

15-A.Z. Momeni, T. Jalayer, M. Emamjomeh, R. Labaf Ghassemi, Y. Dowlaty, A. Khamesipour, I Sharifi: Efficacy trial of single dose killed leishmania major vaccine against natural zoonotic cutaneous leishmaniasis (Randomized double blind study), Mashhad, Iran

16-I Sharifi: Leishmania skin test reacting in pimary school children in the southeastern Iranian city. World leish 2 congress, 2001. 5. 20-24 ,Greece

17-I Sharifi: Lupoid leishmaniasis in school children in Bam southeast Iran. World leish 2 congress, 2001.5. 20-24 ,Greece

18-I Sharifi: Multiple doses of autoclaved leishmania major vaccine against anthroponotic cutaneous leishmaniasis in Bam, Iran. World leish 2 congress, 2001.5. 20-24 ,Greece

19-I. Sharifi: Identification and characterization of cutaneous leishmaniasis species in Kerman province southeast Iran. World leish 2 congress, 2001.5. 20-24 ,Greece

20-Mohmoodi M, A. Khamesipour, Y. Dowlati, I. Sharifi, S. Rafati, F. Modabber: Immune responses measured in human volunteers vaccinated with outoclaved leishmania major plus BCG. World leish 2 congress, 2001.5. 20-24 یونان.

21-A. Khamesipour, V. Dowlati, M. Nilfroushzadeh, A. Javadi, H. Hejazi, Q. Naseri, I. Sharifi, L. Molton, D. Sacks, P. Smith, F. Zicker, F. Modabber: Phase IV efficacy hield trial of multiple doses of autoclaved leishmania major vaccine mined with BCG in children in zoonotic cutaneous leishmaniasis (ZLC) endemic earea. World leish 2 congress, 2001.5. 20-24 Greece

22-H.Vatandoost, M.Mashayekhi ,M.R.Abaie,M.R.Aflatoonian,M.A.Oshagi ,A.A.Hanafi –Bojd ,G.ZAMANI . I. Sharifi : Current malaria epidemiology in a malarious area , kerman province , south –east

Iran. IX EUROPEAN MULTICOLLOQUIUM OF PARASITOLOGY, 18-23 JULY 2004 Valencia, SPAIN.

23-Sharifi I, et al: The Status of Cutaneous Leishmaniasis after the earthquake in Bam, Iran. Third world Congress on Leishmaniasis, 10-15. Apr. 2005. Palermo-Terrasini Siafy, Italy. P. 207.

24-Zemani F, Sharifi I: Epidemic of Cutaneous Leishmaniasis due to *Leishmania major* in the South-eastern Iranian City of Baft. Third world Congress on Leishmaniasis, 10-15. Apr. 2005. Palermo-Terrasini Siafy, Italy. P. 222.

25-Hejazi S.H, Sharifi I, et al: Comparison of *Leishmania* Skin test by Using four different antigen Prepared from *Leishmania major* and *Leishmania tropica*. Third world Congress on Leishmaniasis, 10-15. Apr. 2005. Palermo-Terrasini Siafy, Italy. P. 256.

26-Khamesipour, A. Sharifi, I, et al Differential immune responses to vaccination in populations of non-endemic vs. endemic areas. Third world Congress on Leishmaniasis, 10-15. Apr. 2005. Palermo-Terrasini Siafy, Italy. P. 261.

27-Keshavarz. H, Sharifi. I, et al: Relationship of malaria incidence and ABO blood group. Medicine and Health in the Tropics. Mareille-France, 11-15 Sept. 2005, P374

28-Sharifi.I, Khamesipour.A, et al: Cutaneous Leishmaniasis lesion development in individuals with negative or positive Leishmanin skin test. Medicine and Health in the Tropics. Mareille-France, 11-15 Sept. 2005, p257.

29-Sharifi.I: Cutaneous leishmania in the south-eastern. 11th. International. Congress of Parasitology, 6-11 th August 2006- Glasgow, Scotland.

30-Sharifi I, Aflatoonian MR, Fekri AR, Khamesipour A: Cutaneous leishmaniasis in Bam: Five years before and after the earth quake. 4th World Leishmaniasis Congress –Lucknow India, Feb (7-11) 2009

31-Sharifi I, et al: The synergic effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of *Leishmania tropica* to meglumine antimonite. 4th World Leishmaniasis Congress –Lucknow India, Feb (7-11) 2009.

32-Khamesipour A, Sharifi I, Khatami AR: Comparison of the efficacy of weekly VS. Biweekly intralesional injections of meglumine antimonite in the treatment of acute anthroponotic cutaneous leishmaniasis (ACL). 4th World Leishmaniasis Congress –Lucknow India, Feb (7-11) 2009.

33-Fazaeli A Fouladi B, Sharifi I: Emergence of cutaneous leishmaniasis and a new focus on a border area at southeast of Iran. 4th World Leishmaniasis Congress –Lucknow India, Feb (7-11) 2009.

34-Poursmaelian S. Sharifi I. Aflatoonian M.R., Fotouhi Ardakani R., Mirzaei M, Hakimi Parizi M: Study of a new focus of anthroponotic cutaneous leishmaniasis in Dehbakry region of Bam district, southeastern Iran 2008. The 3rd Iranian Congress of Clinical Microbiology- Shiraz, 6-8 Oct. 2009 Abstract book Page 221.

35-Poursmaelian S, Sharifi I: A new focus of anthroponotic cutaneous leishmaniasis Northern Jiroft. Iranian J Parasitology Supplementary Issue, Vol. 5, S1, 2010, Tehran, Iran; 19-21 Oct, 2010

36-Yoosefi S, Hakimi Parizi M, Sharifi I: Study of funa and seasonal activity on phlebotominae sand flies in Chah Daghigh village, Sirjan district, Kerman province, Sirjan district, Kerman province in 2009.

Iranian J Parasitology Supplementary Issue, Vol. 5, S1, 2010, Tehran, Iran; 19-21 Oct, 2010

37-Zarean M, Sharifi I, Ziya ali N, Fekri A, et al: Identification of cutaneous leishmaniasis agents isolated of smears from patients by Nested-Pcr in Kerman province. Iranian J Parasitology Supplementary Issue, Vol. 5, S1, 2010, Tehran, Iran; 19-21 Oct, 2010

38-Sharifi I, Poursmaelian S, Aflatoonian MR, Hakimi Parizi m , et al: Emergence and reactivation of new and old foci of anthroponotic cutaneous areas after the earthquake

Iranian J Parasitology Supplementary Issue, Vol. 5, S1, 2010, Tehran, Iran; 19-21 Oct, 2010

39-Mahmoudvand H, Mohebbi M, Sharifi I, et al: Study on visceral leishmaniasis (Kalaazar) in human and dogs by serological, molecular and pathological methods in Baft district, Kerman province.

Iranian J Parasitology Supplementary Issue, Vol. 5, S1, 2010, Tehran, Iran; 19-21 Oct, 2010

40-Pour R, Sharifi I, Kazemi B, Zarean M: Identification of resistant isolates to meglumine antimoniate and genetic diversity of MDR1 gene in patients' cutaneous leishmaniasis in Bam.

Iranian J Parasitology Supplementary Issue, Vol. 5, S1, 2010, Tehran, Iran; 19-21 Oct, 2010

41-Barati M, Sharifi I , Sharififar f , Poursmaelian S : Antileishmanial activity of *Artemisia aucheri* , *ferula asa-foetid*, and *gossypium hirsutum* extracts on *Leishmania major* promastigotes in vitro.

Iranian J Parasitology Supplementary Issue, Vol. 5, S1, 2010, Tehran, Iran; 19-21 Oct, 2010

42-Nosratabadi J , sharifi I , daneshvar H , sharififar f. Invitro antileishmanial activity of aquatic and alcoholic extracts of *eucalyptus camaldulensis* on *leishmania major*. Iranian J Parasitology Supplementary Issue, Vol. 5, S1, 2010, Tehran, Iran; 19-21 Oct, 2010.

43-Asgari Nezhad H, Mirzaie M, Sharifi, I, Zarean. M, Norouzi , M: The prevalence of cutaneous leishmaniasis in school in Dehloran, Iran province, south-western Iran, 2010. 4 Iranian Congress of Clinical Microbiology, 9-11 November 2010, Isfahan/Iran

44-Asgari Nezhad H, Mirzaie M, Sharifi, I , Zarean. M , Norouzi , M:The prevalence of cutaneous leishmaniasis in school in Dehloran, Iran province, south-western Iran, 2010 4 Iranian Congress of Clinical Microbiology, 9-11 November 2010, Isfahan/Iran

45-Mirgie . M, Asgari Nezhad H. Sharifi. I : A3-year study of the Epidemiological characteristics in Dehloran county, south-western Iran. 4 Iranian Congress of Clinical Microbiology, 9-11 November 2010, Isfahan/Iran.

46-Mahmoudvand H, Mohebbali M, Sharifi I, et al: A new endemic focus of visceral leishmaniasis (Kala-azar) in Kerman province, southeast of Iran 7th European Congress on Tropical medicine and International Health (Ref: 3596), 3-6 Oct 2011 Barcelona, Spain.

47-Mahmoudvand H, Sharifi I, Fasihi-Harandi M, et al: Several *Plasmodium Vivax* malaria in splenectomized patient. 7th European Congress on Tropical medicine and International Health (Ref: 3592), 3-6 Oct 2011 Barcelona, Spain.

48- Abdolahyar f, Sharifi I, et al: Cutaneous leishmaniasis burden and immunohistochemical analysis in resistant patient in Kerman provinces. 2nd International and 9th National Congress of Parasitology and Parasitic Diseases of Iran, Guilan, Iran; 20-22 May 2015

49- Naderi A, Sharifi I, et al: Epidemiology and clinical manifestations of visceral leishmaniasis and species identity in domestic dogs in southern district of Kerman provinces, Iran, 2013 2nd International and 9th National Congress of Parasitology and Parasitic Diseases of Iran, Guilan, Iran; 20-22 May 2015.

50- Hakimi Parizi M Ghaffari D, Yaghoobi Ershadi MR Sharifi I, et al: A SURVEY OF RESERVOIR HOSTS IN TWO FOCI OF CUTANEOUS LEISHMANIASIS IN KERMEN PROVINCE, SOUTHEAST OF IRAN. 2nd International and 9th National Congress of Parasitology and Parasitic Diseases of Iran, Guilan, Iran; 20-22 May 2015

51- Mostafavi M, Asadikaram GR, Sharifi I, et al: A COMPARATIVE EVALUATION OF THE CUTANEOUS LEISHMANIASIS SEVERITY IN OPIUM ADDICTED PATIENTS AND NON-ADDICTED. 2nd International and 9th National Congress of Parasitology and Parasitic Diseases of Iran, Guilan, Iran; 20-22 May 2015.

52- Tavakoli R, Oliabee, H, Mahmoudvand H, Sharifi I, et al: IN VITRO EFFECT OF NICOTINAMIDE ALONE OR IN COMBINATION WITH GLUCANTIME ON

PROMASTIGOTE AND AMASTIGOTE STAGES OF LEISHMANIA TROPICA. 2nd International and 9th National Congress of Parasitology and Parasitic Diseases of Iran Guilan, Iran; 20-22 May 2015

53- Ghasemi P, Almani N, Sharifi I, et al: DESIGNING AND CLONING OF MOLECULAR CONSTRUCTS TO KNOCK OUT GPI12 GENE IN

LEISHMANIA MAJOR AS AN EXPERIMENTAL MODEL FOR A CANDIDATE VACCINE. 2nd International and 9th National Congress of Parasitology and Parasitic Diseases of Iran Guilan, Iran; 20-22 May 2015.

54- Kamiab H Sharifi I, et al: COMPARATIVE STUDY FOR DIAGNOSIS OF CANINE VISCERAL LEISHMANIASIS USING IFA AND NESTED-PCR IN THE ENDEMIC AREA OF IRAN.

2nd International and 9th National Congress of Parasitology and Parasitic Diseases of Iran Guilan, Iran; 20-22 May 2015.

55- Karimi T, Sharifi I, et al: THE ROLE OF ACTIVE CASE-DETECTION IN FINDING ANTHROPONOTIC CUTANEOUS LEISHMANIASIS PATIENTS IN AN ENDEMIC FOCUS IN SOUTH EASTERN IRAN AND IDENTIFICATION OF THE CAUSATIVE SPECIES AND PHYLOGENETIC RELATIONSHIP OF ISOLATES BY PCR-RFLP AND SEQUENCING.

2nd International and 9th National Congress of Parasitology and Parasitic Diseases of Iran Guilan, Iran; 20-22 May 2015.

56- Abbaszadeh Aafshar MJ, Mohebbi Mohebbi M, Sharifi I, et al:

SERO EPIDEMIOLOGICAL SURVEY OF VISCERAL LEISHMANIASIS AMONG NOMADIC TRIBES OF SOUTH OF KERMAN PROVINCE, SOUTHEASTERN IRAN: AN OBSERVATIONAL STUDY FOR IMPLICATION TO HEALTH POLICY

2nd International and 9th National Congress of Parasitology and Parasitic Diseases of Iran Guilan, Iran; 20-22 May 2015.

57- Ezatkah F, Sharifi I: AN IN VITRO COMPARISON OF NONRESPONSIVE WITH RESPONSIVE ISOLATES TO GLUCANTIME IN A FOCUS OF THROPONOTIC CUTANEOUS LEISHMANIASIS. 2nd International and 9th National Congress of Parasitology and Parasitic Diseases of Iran Guilan, Iran; 20-22 May 2015.

- Books translated

1. How to write and publish a scientific paper. Jahad Daneshgahi Publication Co. p.150, 1990 (Tehran/Iran).
2. The clinical management of acute malaria, WHO Regional publications, South-East Asia Series No.9. Jahad Daneshgahi Publication Co., p. 148, 1993 (Tehran, Iran).
3. Manual on visceral leishmaniasis control. World Health Organization.
4. Division of control. Ministry of Health Publication, p.170, 1999 (Tehran/Iran).
5. Rapid health assessment protocols for emergencies. WHO Publication. Semnan Uni of Med Sci Publications, p. 160, 2001 (Iran).

- Posts Held

1. Head of Clinical Labs of Med. School (1981-1982)
2. Dean of School of Medicine (1982-1984).
3. Chancellor of Shahid Bahaonar Uni (1984-1987)
4. Chancellor of Kerman Uni of Med. Sci and Director of provincial Health System (1987-1990)
5. Steering Committee Member (TDR/WHO) for 2 years (1995-1997)
6. Head of Microbiology and Parasitology Department (1990-1997)
7. Vice Chancellor for Research-Kerman Uni of Med Sci (1996-1998).
8. Chancellor for Kerman Uni Med Sci (1998-2005).
9. Head of Parasitology Dept & Director of Kerman Leishmaniasis Research Center (2005-present).

- Courses Taken

1. Workshop on Leishmania typing using Monoclonal Antibodies and Excreted Factors (March 13-18, 1995). Casablanca.
2. Parasitic Disease: Advanced Laboratory Diagnosis (2-13 September-1996). London School of Hygiene and Tropical Medicine.
3. Educational Methodology Course, 9-21 Dec. 1996 Uni of Journal, Center for educational development/ sponsored by WHO.
4. Workshop on General Research Methodology, 11-17 Sep 1997, Tehran, Iran.
5. Workshop on Advanced Research Methodology, 16-22 Aug 2000 Meshad, Iran.

- Research Projects Taken from WHO/TDR

1. Situation analysis and needs assessment to help program in preparation of an elimination plan for cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL) in Iran for a period of 4 years, 2019-2022 (consultant contract 202096276).
2. Protocol for reviewing and strengthening system for leishmaniasis in Iran (present).
3. Double blind, randomized clinical trial on efficacy of combination of meglumine antimoniate (Glucantime) and topical nano-liposomal paromomycin for the treatment of anthroponotic cutaneous

Leishmaniasis (ACL) caused by *Leishmania tropica* (Phase 3), funded by WHO/EMRO Proposal ID No SGS 10/69.

4. Evaluation of efficacy of intra-lesional injections of Glucantime once weekly in comparison with twice weekly in the treatment of acute Anthroponotic Cutaneous Leishmaniasis (ACL), CRTSDL, TUMS, 2007-2008.
 5. Randomized open clinical trial on the efficacy of oral miltefosine in comparison with Glucantime in the treatment of anthroponotic cutaneous Leishmaniasis (ACL) caused by *L. tropica*. ID No. SGS05/97, EMRO/TDR. 2006-2008.
 6. Production, standardization, QC and preclinical testing of live *Leishmania major* as the basis for the establishment of a LZ platform. WHO/IVR. 2006-2008.
 7. The critical role of the choice of human volunteers in anti-*Leishmania* vaccine trials. Swedish International Development Cooperation Agency (SIDA), Sweden, 2006-2008.
 8. Leishmanization as live challenge for evaluation of candidate vaccine and protection against Leishmaniasis. TDR/WHO, ID NO. 980827.
 9. Coordinator of TDR projects and leishmaniasis clinical trials in Iran. TDR/WHO, ID NO. 981013.
 10. Collaborating research on leishmaniasis and malaria in Iran. TDR/WHO, ID NO. 981134.
 11. Phase III efficacy field trial of multiple doses of autoclaved *Leishmania* vaccine (ALM). TDR/WHO, ID NO. 980461.
 12. Part 1, the epidemiology of malaria in Kahnouj in preparation for conducting a vaccine trial, Kerman province, Iran part II, knowledge, practices and perceptions about malaria in rural communities of Kahnouj.
 13. Part III, Designing GIS for control and management of malaria in Kahnouj. Multi- central project with WHO/ TDR/RCS.
 14. Single dose of autoclaved *Leishmania major* (ALM) vaccine against anthroponotic cutaneous leishmaniasis (ID no. 931190), 1993-1996.
 15. Multiple doses of ALM vaccine against ACL (ID no. 970214), 1996-1999
-